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ABSTRACT 
 
Adam J. Filgo: Early life chemical exposures and latent mammary effects in                     
male and female rats 
(Under the direction of Suzanne E. Fenton) 
 
Volatile organic compounds (VOCs) are common industrial solvents used in a 
number of cleaning agents and solvents. In the United States, spikes in birth defects, infant 
mortality, reproductive cancers and leukemia have occurred in areas with high levels of 
VOCs in drinking water. My thesis is focused on the effects of a VOC mixture on mammary 
gland development and risk for mammary tumor formation following prenatal/perinatal 
exposures in a 7,12-Dimethylbenz(a)anthracene (DMBA)-induced mammary tumor rat 
model. To gain an understanding of the animal model used in my studies, the Harlan Sprague 
Dawley (HSD) rat, an atlas of mammary gland development was created for both sexes, 
starting at embryonic day 15.5 through postnatal day (PND) 70. In addition, prenatal 
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin  and diethylstilbestrol were used to 
demonstrate delayed and accelerated mammary gland growth, respectively. This atlas of 
mammary gland development in the HSD rat will be a key component in understanding and 
interpreting effects of chemicals in this rat strain. To specifically test the VOC mixture in this 
rat model, time-pregnant HSD rats and their offspring were given access to water containing 
a mixture of VOCs at concentrations 5X, 10X and 50X times those detected in contaminated 
drinking water at Camp Lejeune, to determine VOC body burden in both dams and pups. 
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Mammary gland development was found to be accelerated in both sexes at the 5X and 10X 
concentrations. DMBA was given to VOC-exposed animals at PND 30 and tumors were 
recorded and collected 26 weeks after carcinogen treatment. There was a significant trend 
increase in adenocarcinomas arising in a fibroadenoma with VOC exposure in the females. 
Additionally, two malignant tumors formed in the males in the 10X exposure group and the 
males that died early due to tumor burden were from the 10X exposure group. These data 
demonstrate the ability of the VOC mixture to accelerate mammary gland development and 
enhanced the risk for tumor formation following carcinogen exposure. The mixture of VOCs 
was active at only 5-10 fold higher levels than what Marines or their mothers might have 
consumed, and these low level, prenatal exposure effects deserve further attention.
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CHAPTER 1: Introduction 
 
My thesis work has focused on a human health problem that became known in the 
popular press. It was based on a 30-year contamination event that left many middle aged 
male Marines and the children of Marines  wondering why they may have been diagnosed 
with breast cancer. 
Breast cancer is the most commonly diagnosed cancer in women, and after lung 
cancer, is the second most common fatal cancer of women [1]. In 2014, there was an 
estimated 232,670 new cases of invasive breast cancer diagnosed in women in the United 
States, which equates to about 1 in every 8 women [2]. The peak age range for diagnosis of 
breast cancer in women is 55-64[1]. In 2004, there was a decrease in the breast cancer 
incidence rate of almost 7% due to reductions in use of hormonal replacement therapy in 
post-menopausal women. Between 2006 and 2010, breast cancer incidence rates have 
remained stable and deaths from breast cancer have steadily decreased [3]. Breast cancer in 
men is uncommon and accounts for about 0.5-1% of total breast cancers [2]. In 2014, less 
than 1 in 1000 men developed breast cancer with an estimated 2360 new cases in the United 
States [3, 4].  Unlike breast cancer in women, male breast cancer incidence peaks at 71 years 
of age and the incidence rates may be slowly rising [5, 6].  It has been estimated that fifteen 
percent of breast cancers in men are familial [6]. Most diagnoses of breast cancer, in both 
men and women, are without associated breast cancer susceptibility gene mutations.    
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Known risk factors for women include: family history, genetic variants (BRCA1, 
BRCA2, TP53, PTEN, etc.), breast density, history of benign breast disease, reproductive 
factors (increased lifetime exposures to estrogen and progesterone and not having children), 
physical activity, alcohol consumption, radiation exposure, and adult body mass [7, 8]. 
Potential risk factors for men include; family history, estrogen excess (medication, 
Klinefelter syndrome), genetic variants (similar to those in women), occupational exposures 
to radiation, carcinogens and potentially volatile organic compounds [4, 6].   Interestingly, 
environmental and lifestyle factors contribute to 70–95 % of breast cancer risk [9]. Even 
familial breast cancer risk is speculated  to be the interaction between lifestyle factors and 
common gene variations (that only add a small increase in breast cancer risk) [3].  
Exogenous chemical exposures (aryl aromatic amines, N-nitrosamines, tobacco 
smoke, etc.) have had significant correlations with risk for breast cancer development in 
epidemiological studies around the globe [8]. However, it is difficult to prove causation 
because the disease is often diagnosed decades after environmental exposures and humans 
are not exposed to one chemical. Even when causation may be attributed to a particular 
environmental exposure, such as in rodent model studies in a controlled environment, it is 
often complicated to determine a mechanism by which it affects the mammary tissue due to 
the complexity of the gland and its intricate signaling pathways. There are windows of 
susceptibility in mammary gland development, not common to other organs, when 
exogenous chemical exposures could influence breast development and increase breast 
cancer risk [7]. 
The mammary glands of both humans and rodents undergo four phases of critical 
growth and development; in utero, neonatal, puberty and pregnancy followed by involution. 
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Little is known about the mechanism of fetal breast formation in humans, but in rodents 
mammary gland development involves communication between the epidermis and 
mesenchyme by various signaling pathways [10, 11]. The known signaling events of rodent 
embryonic female mammary gland development from milk line formation to rudimentary 
ductal tree present at birth have been described [12]. The milk line requires early Wnt 
signaling and leads to the formation of the mammary placode, a thickening in the epithelial 
layer and the first sign of mammary gland formation [13]. The rodent mammary bud then 
forms due to a number of signaling peptides expressed within either the epithelial or 
mesenchymal cells including; Wnt 11, β-catenin and sex steroid hormone receptors like 
estrogen receptor α/β (ERα/β) and androgen receptor (AR). The rudimentary ductal tree 
development from the mammary bud is known to be hormone independent, while regulation 
of the initial phase of ductal growth is not understood [12]. Male and female rodents have 
morphologically different mammary glands in utero, while human mammary glands are not 
sexually dimorphic until puberty. Male mice have a two day surge of fetal androgens at 
embryonic day (E) 13.5-15.5 that causes apoptosis of the mammary epithelium and 
regression may eliminate the mammary epithelium [14]. In male rats, due to the androgen 
surge that occurs around E17 the epithelial bud becomes separated from the epidermis and no 
nipples are formed, but the rudimentary ductal tree is intact [15]. In humans there is evidence 
that maternal hormones play a part in growth and development of the mammary glands of 
fetuses and newborns [16]. While not found in rodents, lobular structures have been seen in 
newborn infants, and are thought to be a transient structure that dissipates weeks after birth 
[17].  
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Before the onset of puberty, isometric mammary gland growth continues in both 
rodents and humans, independent of hormones [18]. Allometric, or exponential, mammary 
growth during puberty is dependent on several hormones and paracrine signaling. In rodents, 
allometric growth is initiated by ovarian steroids. Estrogen and the growth factors triggered 
by ER activation (epidermal growth factor, growth hormone and insulin-like growth factor-1) 
signal ductal elongation. Ductal branching and alveolar budding are signaled by 
progesterone, prolactin, and thyroid hormone [14, 19]. Some genes that are known to control 
mammary growth during puberty include; inhibin B, colony stimulating factor-1, the 
progesterone receptor (PR), and Wnt [19]. In humans, regulation of allometric growth is less 
clear. Acini form on the terminal ducts and embed in intralobular stoma to form terminal duct 
lobular units (TDLUs), which are the functional units of the breast [17].  Both endocrine and 
paracrine signaling may also stimulate mammary gland growth in humans, but specific 
effects are uncertain [14]. Male mammary glands in humans normally do not develop further 
during puberty [17]. During pregnancy, alveolar proliferation and full differentiation takes 
place in the rodent mammary gland due to progesterone, placental lactogens, prolactin, 
osteoclast differentiation factor and the Jak2-Stat5 signaling pathway [19]. In both humans 
and rodents there is an increase in the number of lobules and a loss of fat in adipose cells of 
the mammary gland during pregnancy and lactation [17]. Lactational involution of the 
mammary gland occurs after weaning of the infant. After weaning, the TDLUs decrease in 
number and size, but the ducts are not involved. During the type of involution that occurs 
with aging (and not lactational), both the TLDUs and the ducts are reduced in number and 
are replaced with collagen and fat [17]. In rodents, tissue remodeling and cell death during 
lactational involution are controlled by Stat3, bax, and bcl-x [19]. The mammary gland is one 
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of the few truly dynamic organs and undergoes many periods of proliferation and 
remodeling. For this reason, carcinogens and endocrine disruption chemicals (EDCs) are 
thought to target the mammary gland. The timing and length of these growth periods may 
vary across species and may affect carcinogen susceptibility. Some of the potential variations 
between strains of the rat species will be addressed in Chapter 2, as it is important to 
understand the animal model for translation to humans. Further investigation of the 
susceptibility of the mammary gland during periods of growth and development is needed to 
understand lifelong breast cancer risk. 
The negligence in examination of the potential role of the environment in risk for 
breast cancer in men took a turn in 2009. CNN reported that 20 people, all Marines or sons of 
Marines based at Camp Lejeune, had been diagnosed with early life male breast cancer and 
that they blamed chemicals in contaminated well water [20]. The Marine Corps Base, Camp 
Lejeune, located in Jacksonville, North Carolina is the site of one of the worst ground water 
contamination events in U.S. history. Between 1953 and 1987, ground water wells were 
contaminated with volatile organic compounds (VOCs) from off-base ABC One Hour 
Cleaners (a dry cleaning facility), on-base metal degreasing and/or leakage from underground 
fuel storage. Among the 70 contaminates measured in the well water, 1500 parts per billion 
(ppb) of tetrachloroethylene (PERC), 50 ppb of trichloroethylene (TCE), 100 ppb of trans-
1,2-dichloroethylene (trans-1,2-DCE), 25 ppb of  vinyl chloride (VC) and 50 ppb of benzene 
were detected in the water supply[21]. These five VOCs are examined in this dissertation for 
their potential effects on mammary gland development and susceptibility to cancer. The 
Agency for Toxic Substances and Disease Registry (ATSDR) reports that compared with the 
Camp Pendleton workers in California, who were not exposed to VOCs, the Camp Lejeune 
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workers had higher mortality rates for leukemia, multiple myeloma, Parkinson ’s disease, 
kidney disease and cancers of the female breast, kidney, lung, oral cavity, prostate, and 
rectum [22]. Additionally, at least 84 men living or serving at Camp Lejeune developed 
invasive breast cancer [23]. Environmental exposure to VOCs during windows of 
susceptibility could be an important environmental factor in breast cancer risk. As low dose, 
mixture studies of VOC exposure during mammary gland development have not yet been 
preformed, the overarching goal of this dissertation project was to evaluate the role of an 
environmentally relevant mixture of VOCs, given during critical windows of susceptibility, 
on mammary gland development and later susceptibility to cancer in male and female rats. In 
Chapter 2, the mammary gland development of the Harlan Sprague Dawley (HSD) rat is 
extensively evaluated, in both the male and female. Defining this rat model provides an aide 
in toxicological assessment of chemicals on the mammary gland. Chapter 3 sets out to better 
understand VOC exposure in sensitive subpopulations of rats; namely the pregnant mother 
and her development offspring. Chapter 4 addresses the key question of whether early life 
VOC exposure alters mammary gland development or affects vulnerability to carcinogens. In 
Chapter 5, the novel findings, limitations, impacts on science and future studies are 
summarized and further discussed. 
Background on Volatile Organic Compounds (VOCs) 
 VOCs have become common ground water contaminates due to their physical and 
chemical properties that allow them to easily move between air, soil and water [24]. VOCs 
are a family of organic chemicals that usually have high vapor pressure, low to medium 
water solubility and low molecular weight. VOCs are formed naturally, industrially, or 
sometimes both [24, 25]. Of the five VOCs of interest in this dissertation all but DCE have 
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been extensively studied by the National Toxicology Program (NTP), U.S. Environmental 
Protection Agency (EPA) and the International Agency on Cancer Research (IARC). The 
following background information is a compilation of data from their risk assessment papers; 
NTP Report on Carcinogens, EPA Support of Summary Information on the Integrated Risk 
Information System and IARC Monographs. 
Benzene 
 Benzene is an aromatic compound and ranks in the top 20 in production volume for 
chemicals produced in the United States. At room temperature, it is a colorless liquid that is 
only slightly soluble in water. It has a sweet odor and is highly flammable. Benzene can 
occur naturally; sources include gas emissions from volcanos and combustion events such as 
forest fires and the burning of tobacco. Benzene is also produced in large quantities and is 
used as a solvent, to synthesize other industrial chemicals, and in a variety of products like 
rubber, drugs and pesticides [24, 26, 27]. Structural, chemical and physical properties are 
shown below. 
 
Figure 1.1. Chemical structure of benzene. Obtained from a Google image search.  
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Table 1 -1. Chemical and physical properties of benzene[27]   
Property  Information 
Molecular weight 78.1 g/mol 
Specific gravity 0.8787 at 15°C/4°C 
Melting point 5.5°C 
Boiling point 80.1°C 
Log Kow 2.13 
Water solubility 1.79 g/L at 25°C 
Vapor pressure 94.8 mm Hg at 25°C 
Vapor density relative to air 2.8 
 
Exposure 
 Benzene is ubiquitous in the atmosphere and has been identified in the air, water or 
soil over 1,000 hazardous waste sites [26]. Benzene is released into the environment 
naturally, but more importantly through anthropogenic emissions such as gasoline vapors, 
auto exhaust and chemical production. Benzene is chemically degraded in a matter of hours 
to days in the air, primarily due to reactions with naturally occurring hydroxyl radicals. 
Volatilization, photo-oxidation, and/or bacterial-biodegradation of benzene in the soil and 
water can break it down in a few weeks under aerobic conditions or several months under 
anaerobic conditions [26, 28]. Benzene has been detected in ground water samples in 832 of 
the 1684 National Priorities List sites [26]. Sources of benzene in ground water include 
underground fuel storage leaks, accidental spills and leaching from contaminated soils[26, 
28].  
The primary route of human exposure to benzene is inhalation of tobacco smoke and 
ambient air, with higher exposures in areas of high vehicle traffic and gas stations. Benzene 
is readily absorbed via inhalation, oral and dermal exposure. Benzene is detected in the blood 
of 100% of smokers and 45% of non-smokers with a mean concentration of 0.136 µg/L and 
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0.024 µg/L, respectively [29]. From the blood, benzene quickly distributes throughout the 
body and tends to accumulate in fatty tissues. The liver is the major site of metabolism and 
production of several reactive metabolites. Benzene can also cross the placenta and enter the 
cord blood where it has been detected at similar levels as found in the mother’s blood [26, 
28].  
Toxicity 
 There are many known human health effects caused by benzene inhalation. It is well 
established that benzene can cause hematological, dermal, immunological, neurological and 
reproductive effects in humans. However, the most significant effect in humans is cancer; 
acute non-lymphocytic leukemia, non-Hodgkin’s lymphoma and multiple myeloma, in 
particular [26].  There is no information on the oral carcinogenicity of benzene in humans, 
but benzene has been shown to be a multiple site carcinogen in chronically adult-dosed 
animals. In adult rats receiving 25-200 mg/kg/day of benzene by gavage in corn oil, there 
were significant increases in Zymbal gland carcinomas, oral cavity squamous cell papilloma 
and carcinomas and skin squamous cell papilloma and carcinomas. In chronically exposed 
adult mice, orally-administered benzene caused a significant increase in the incidence of 
malignant lymphomas, Zymbal gland carcinomas, lung alveolar/bronchiolar adenomas and 
carcinomas, Harderian gland adenomas, preputial gland squamous cell carcinomas and 
female mammary gland carcinomas [30]. 
Regulatory Measures 
 Regulatory steps have actually been taken for benzene. The U.S. EPA has classified 
benzene as Category A; a known human carcinogen[31]. IARC concluded that benzene is a 
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Group 1 contaminant;  carcinogenic to humans [32]. The NTP also identified benzene as a 
known human carcinogen in its Report on Carcinogens. These classifications are based on 
human evidence and supported by animal studies that benzene exposure has a causal 
relationship with cancer [26]. Due to its known human carcinogenic potential, the transport 
and emission levels, exposure limit, and maximum contaminant level of benzene have all 
been extensively regulated by many Agencies including the Department of Transportation, 
U.S. EPA, Food & Drug Administration and Occupational Safety and Health Administration. 
Benzene is considered a hazardous material and requires special labeling and handling. The 
U.S. EPA set the maximum contamination level (MCL) of benzene at 0.005mg/L in drinking 
water. OSHA’s permissible exposure limit of benzene in the work site is set at 1ppm over 8 
hours [27]. 
Tetrachloroethylene (PERC) 
  PERC, a.k.a. perchloroethylene, is a nonflammable, halogenated alkene that is a 
colorless liquid at room temperature. PERC is a man-made VOC. It is primarily used as a 
cleaning solvent in dry cleaning, textile production and metal degreasing and as a chemical 
intermediate [33]. Structure, chemical and physical properties are shown below. 
 
Figure 1.2 Chemical structure of PERC. Obtained from a Google image search.  
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Table 1.2 Chemical and physical properties of PERC[33]   
Property  Information 
Molecular weight 165.8 g/mol 
Specific gravity 1.6227 at 20°C/4°C 
Melting point -22.3°C 
Boiling point 121.3°C 
Log Kow 3.4 
Water solubility 206 mg/L at 25°C 
Vapor pressure 18.5 mm Hg at 25°C 
Vapor density relative to air 5.7 
 
Exposure 
 Humans are thought to be exposed to PERC through inhalation and ingestion of 
contaminated drinking water or food. Indoor air of buildings containing dry-cleaning services 
has higher concentrations of PERC compared to the indoor air from building without dry-
cleaning services. Breath concentrations of PERC are significantly higher in dry cleaners and 
their family members (0.65ppm and 0.05ppm, respectively) compared to controls ( 0.001 
ppm) [34]. Blood concentrations from the National Health and Nutrition Examination Survey 
(NHANES) participants ranged from below the limit of detection to ng/mL [34]. Higher 
blood levels have been found in occupationally exposed workers and populations with highly 
contaminated drinking water. Reported levels of PERC in breast milk have ranged from 
undetectable up to 43 μg/L in the general population [35]. PERC is released into the air 
primarily from manufacturing and processing facilities. The highest emissions come from the 
dry cleaning industry; however storing dry-cleaned garments can slightly raise the PERC 
levels in homes [33, 34, 36].  
PERC degrades slowly and has an estimated half-life of 100 days in the air. PERC 
can also contaminate groundwater where it can persist for decades. Contaminations can occur 
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from improper disposal of chemicals from drying cleaning facilities or degreasing activities, 
which generate aqueous PERC waste. PERC biodegrades by reductive dechlorination and 
produces other potentially harmful chemicals, including TCE, trans-1,2-DCE and VC. PERC 
has been identified in at least 945 hazardous waste sites and detected in approximately 4% of 
U.S. aquifers. The median concentration in the aquifers was 0.09µg/L, and 0.7% of the 
samples exceeded the MCL for drinking water of 5µg/L[34]. 
Toxicity 
 Numerous studies have been conducted to assess the hazard and health risk of PERC 
exposure. Epidemiological and animal studies suggest the primary targets for PERC toxicity 
are the liver, kidney, nervous system and reproductive system. In humans, PERC has been 
associated with increased liver size, slight renal effects, decrements in nervous system 
function and spontaneous abortion. The limitation in most of the human studies is that 
humans are rarely exposed to just PERC. Other VOCs, such as the breakdown products of 
PERC, are often present. PERC is believed to directly affect the nervous system while 
metabolism to oxidative metabolites is thought to result in liver, renal and reproductive 
toxicities [34, 37]. 
 PERC is potentially a human carcinogen. In human epidemiological studies with high 
quality exposure-assessment, PERC exposure was associated with bladder, multiple myeloma 
and non-Hodgkin’s lymphoma [37]. Other studies in humans suggest an association with 
esophageal, kidney, lung, liver, cervical, and breast cancer, but these studies are often 
inconsistent [34].  
Regulatory Measures 
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The NTP determined that PERC is reasonably anticipated to be a human carcinogen 
based on sufficient evidence of carcinogenicity from studies in experimental animals [33]. 
IARC concluded that PERC was probably carcinogenic to humans (Group 2A) based on 
limited evidence in humans and sufficient evidence in experimental animals [36]. The U.S. 
EPA also determined that PERC is likely to be a human carcinogen[37]. PERC is considered 
a hazardous material and is highly regulated. The MCL set by the EPA is 0.005 mg/L in 
drinking water and the permissible exposure limits set by OSHA is 100 ppm over 8 hours 
[33]. 
Trichloroethylene (TCE) 
 Trichloroethylene is a halogenated alkene and at room temperature is a colorless 
liquid, with moderate water solubility. Although it is a natural breakdown product of PERC, 
TCE is predominantly man-made to serve as an intermediate for hydrofluorocarbon 
production and as a solvent for metal degreasing [38]. Structure, chemical and physical 
properties are shown below. 
 
 
Figure 1.3 Chemical structure of TCE. Obtained from a Google image search.  
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Table 1.3 Chemical and physical properties of TCE[38] 
Property  Information 
Molecular weight 131.4 g/mol 
Specific gravity 1.4642 at 20°C/4°C 
Melting point -84.7°C 
Boiling point 87.2°C 
Log Kow 2.61 
Water solubility 1.28 mg/L at 25°C 
Vapor pressure 69 mm Hg at 25°C 
Vapor density relative to air 4.53 
 
Exposure 
 Inhalation and ingesting contaminated drinking water are the main routes of exposure 
to TCE in humans. TCE is a major ingredient in some household aerosols, adhesives, paint 
removers and degreasers (primarily for crafters and hobbyists). TCE has been found in food 
items, like avocados, and is likely due to contaminated water in food processing or 
degreasing of food processing equipment. TCE production has been declining over the last 
two decades and rural areas have lower levels than urban environments [36, 39, 40]. In the 
U.S., mean TCE concentrations have been determined for rural (0.03 ppb) and urban areas 
(0.460 ppb), and in areas near emission sources of TCE (1.2 ppb) [40]. In yearly monitoring 
of public water systems, TCE was detected in 4.9% of ground water samples and 14.8% of 
surface water samples. The median and maximum concentrations were 1.1 ppb and 159 ppb 
and 1.6 ppb and 50 ppb, for ground and surface water, respectively. According to NHANES,  
about 10% of the U.S. populations  have detectable levels of TCE in their blood with a mean 
concentration of 0.017µg/L (ppb)[38].  
 Once TCE is released into the atmosphere it is degraded by reacting  with hydroxyl 
radicals and has a half-life in air of about 7 days [40]. It is persistent in the environment due 
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to its constant release and potentially from formation as a breakdown product of the much 
more environmentally persistent PERC. TCE degrades much slower in water and will off-gas 
from surface water before degrading. Reductive dehalogenation by microorganisms can 
occur but at a very slow rate and TCE persists much longer in soil and underground water. 
TCE is the most frequently reported organic contaminant in groundwater. Industrial 
discharge of wastewater into streams is a major source of TCE contamination. TCE can also 
leach into the groundwater from landfills and has been identified in at least 1045 hazardous 
waste sites[40]. 
Toxicity 
 TCE poses a potential human health hazard to the central nervous system, kidney, 
liver, immune system, male reproductive system, and developing fetus. Human and animal 
studies have demonstrated that TCE exposure is associated with trigeminal nerve impairment 
(the nerve source for somatic sensation over the entire face, the eye, the nasal passages and 
the oral cavity) and vestibular system impairments (headaches, dizziness and nausea) [41]. 
TCE causes nephrotoxicity in the form of tubular toxicity. TCE exerts its actions 
predominantly through the metabolite S-dichlorovinyl-L-cysteine. TCE has been shown to 
cause some liver toxicity in animals, but there is only limited epidemiological evidence of 
TCE causing changes in liver function tests or liver toxicity [41]. 
Regulatory Measures 
The NTP determined that TCE is reasonably anticipated to be a human carcinogen 
based on limited evidence of carcinogenicity from studies in humans and sufficient evidence 
from studies in experimental animals [38]. IARC determined that TCE is carcinogenic to 
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humans (Group 1) based on sufficient human and experimental animals studies [36]. EPA 
concluded TCE is carcinogenic to humans based on convincing evidence of a causal 
association between TCE exposure in humans and kidney cancer [41]. 
trans-1,2-Dichloroethylene (trans-1,2-DCE) 
 1,2-Dichloroethylene is also called 1,2-dichloroethene (DCE). It is a highly 
flammable, colorless liquid with a harsh odor. There are two forms of DCE; one form is cis-
1,2-DCE and the other is trans-1,2-DCE. Sometimes both forms are present as a mixture. 
DCE is used most often as an ingredient of solvents and in chemical mixtures [42, 43]. 
Structure, chemical and physical properties of trans-1,2-DCE are shown below. 
 
 
Figure 1.4 Chemical structure of trans-1,2-DCE. Obtained from a Google image 
search.  
Table 1.4 Chemical and physical properties of trans-1,2-DCE [44] 
Property  Information 
Molecular weight 96.94 g/mol 
Specific gravity 1.2565 at 20°C/4°C 
Melting point -49.8°C 
Boiling point 48.7°C 
Log Kow 2.06 
Water solubility 4,520 mg/L at 25°C 
Vapor pressure 331 mm Hg at 25°C 
Vapor density relative to air 3.67 
 
 
17 
 
Exposure 
 The major route of exposure to the general population is through ingestion of 
contaminated drinking water. DCE may enter groundwater by leaching from contaminated 
waste disposal sites or more likely degradation of PERC or TCE. The general population in 
urban areas may also be exposed to low levels (0.013-0.076 ppb) in the air [43]. Sources of 
air-borne DCE are emissions from production companies, waste disposal sites and 
volatilization from contaminated waste waters. 
 DCE reacts with hydroxyl radicals in the air and the estimated atmospheric lifetime 
for trans-1,2-DCE is 5 days. In groundwater, DCE can slowly undergo further degradation to 
VC and potentially has a half-life of a couple months. Concentrations of DCE isomers 
detected in U.S. groundwater ranged from 0.25 to 0.28 ppb. Of the tested sources, DCE has 
been found at detectable concentrations in less than 5% of surface water sources and 21% of 
groundwater sources[43]. 
Toxicity 
Very few studies have been conducted on DCE and human health concerns. There has 
been one documented death from excessive inhalation in the 1930’s, but no symptoms of 
toxicity were reported. Inhalation of trans-1,2-DCE at high concentrations is known to 
depress the central nervous system and cause nausea, drowsiness and fatigue. DCE is 
considered fairly nontoxic to animals. The LD50 of trans-1,2-DCE is 7,900mg/kg in male 
Sprague Dawley rats when delivered via gavage [42]. Inhalation of trans-1,2-DCE at 200 
ppm caused liver changes (fatty accumulation in lobules and Kupffer cells) and this study is 
the basis of the occupational inhalation MCL of 0.2 ppm [43]. There is no oral MCL for 
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trans-1,2-DCE and the numerous safety assessments have found that there is “inadequate 
information to assess the carcinogenic potential” of trans-1,2-DCE [45]. 
Vinyl Chloride (VC) 
 Vinyl chloride is a halogenated olefin compound that is very flammable and at room 
temperature is a colorless gas. Vinyl chloride is used by the plastics industry to produce 
polyvinyl chloride, which is used in many consumer and industrial products [46]. Structure, 
chemical and physical properties are shown below. 
 
 
 
Figure 1.5 Chemical structures of VC. Obtained from a Google image search.  
Table 1.5 Chemical and physical properties of VC [47] 
Property  Information 
Molecular weight 62.5 g/mol 
Specific gravity 0.9106 at 20°C/4°C 
Melting point -153.7°C 
Boiling point 13.3°C 
Log Kow 1.62 
Water solubility 8.8 mg/L at 25°C 
Vapor pressure 2980 mm Hg at 25°C 
Vapor density relative to air 2.15 
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Exposure 
 The major route of exposure to the general population is inhalation and ingestion of 
contaminated drinking water. Smoking may also expose individuals to VC. Unless living 
near emission sources, the general population is rarely exposed to VC. Ambient air does not 
typically contain detectable levels of VC, however near emission sources levels can range 
from trace to 2,600µg/m
3
[48]. VC is rarely detected in public drinking water; the U.S. EPA 
estimates that 0.9% of the U.S. population is  exposed to 1 µg/L or higher VC and only 0.3% 
of the population is exposed to higher than 5 µg/L. Occupational exposure is the most 
common way the population is exposed to VC [48-50]. 
 VC is primarily a man-made substance, but can naturally be formed from the 
breakdown of PERC or TCE. VC is mostly released from VC and PVC manufacturing plants 
but can leach into groundwater from spills and landfills. VC in the atmosphere is removed by 
reacting with hydroxyl radicals and has a very short half-life of a few hours. The half-life of 
VC in groundwater is much longer than in the air. There are certain microorganisms and 
chemical reactions that can degrade VC however; volatilization is the main route of transport 
out of water. VC has been identified in at least 622 hazardous waste sites [48]. 
Toxicity 
 VC is known to have toxic effects on several organ systems, with liver being the most 
sensitive in animal studies. High doses, such as those experienced in occupational settings, 
can cause neurological effects, such as headaches, dizziness, loss of consciousness and 
Raynaud’s phenomenon (numbness in fingers and cold sensitivity) [48]. VC is associated 
with liver impairment and damage and is strongly associated with liver angiosarcoma in 
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humans [49]. Angiosarcoma is a neoplasm arising from vascular endothelial cells in the liver, 
and is rare in humans. Other tumors may be associated with VC such as, liver cancers, brain 
soft tissue and nervous system cancer. VC metabolites, chloroethylene epoxide and 
chloroacetaldehyde, are both genotoxic and can form DNA and protein adducts [48]. 
Regulatory Measures 
Animal studies have confirmed the carcinogenicity of VC in several rodent species 
and via different routes of exposure. Liver, mammary, skin, lung and Zymbal’s gland tumors 
have all been associated with VC exposure in the rat [48]. The U.S. EPA has classified VC as 
Category A, a known human carcinogen [49]. IARC classified VC as Group 1; carcinogenic 
to humans [50]. The NTP also determined that VC is a known human carcinogen [46]. These 
classifications are based on human evidence and supported by animal studies that VC 
exposure has a causal relationship with cancer. 
Men and women were exposed to VOCs at Camp Lejeune in a manner that was not 
recapitulated in the 2 year bioassays of PERC, TCE, VC and benzene. Rats and mice were 
exposed to high concentrations of VOCs as adult animals and to a single compound, via 
inhalation or oral gavage.  Marines and the children of the Marines stationed at Camp 
Lejeune were exposed to a mixture of VOC at a low concentration, rather than a single 
compound. Children of Marines could have been exposed to VOCs in utero, as young 
children and/or during puberty and the Marines themselves could have been as young as 17 
when stationed there. In addition, VOC exposure likely occurred by both ingestion and 
inhalation. Any three of these differences in VOC exposure could have made the mammary 
gland a sensitive developing target organ and led to an increased risk of developing breast 
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cancer. This dissertation will address the first two key differences in exposure to VOCs and 
will discuss the limitations and future directions with inhalation and oral exposure to VOCs.  
My hypothesis is the following: human relevant drinking water exposure to VOCs, during 
critical periods of mammary gland development, will alter mammary gland development and 
increase susceptibility to DMBA-induced tumor formation in male and female HSD rats. 
Before evaluating the effects of VOCs on the mammary gland, Chapter 2 will define both 
normal and chemically altered male and female HSD rat mammary gland development. 
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CHAPTER 2: An Atlas of Mammary Gland Development in Male and Female Harlan 
Sprague Dawley Rats: Examples of Accelerated and Delayed Development
1 
Introduction 
The mammary gland is a complex tissue made of multiple cellular compartments: the 
epithelium and the surrounding stroma, which includes fibroblasts, adipocytes, and immune 
cells [1]. Mammary gland development is orchestrated by many different hormones and 
growth factors [2]. Rapid mammary gland development occurs during embryogenesis, 
puberty, pregnancy and lactation.  Unlike most organs, the majority of mammary gland 
development occurs after birth. Although there are specific differences in timing, female 
human and rodent mammary glands undergo a similar developmental process [3, 4]. During 
embryogenesis, the mammary bud and the resulting primary duct extend into the developing 
mammary fat pad. Secondary side branching of the primary duct occurs and a small ductal 
tree is present at the time of birth. Prior to puberty, the gland undergoes isometric growth and 
as puberty progresses, the ductal growth occurs exponentially. In adulthood, the mammary 
gland enters a resting static state with slight hormone-induced changes in the female related 
to the estrous cycle [5]. At this point, the overall structure of the adult female mammary 
gland is tubuloalveolar, meaning that the gland is composed primarily of ducts with lumens. 
Starting at pregnancy and continuing through lactation, the overall structure of the mammary 
________________________                                                                                                
1This chapter has been submitted as an article in the Journal of Toxicologic Pathology by the authors: Filgo, 
A.J.,  Foley, J.F., Borde, A.R., Reed, C.E., Chappell, V.A., Alexander, L.B.,  Borde, P.R., Hayes, S.A., and 
Fenton, S.E. 
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gland changes and becomes lobuloalveolar, where alveolar lobules, surrounded by the 
myoepithelium, are the predominant structures serving the function of milk production. 
Improper mammary gland development has very important health consequences at 
different life stages. There is accumulating evidence in rodents that fetal exposure to certain 
chemicals may lead to inappropriate development of the mammary gland in offspring, which 
may lead to nipple/areola retention in males and enhanced or delayed ductal development in 
females [6]. During puberty, endocrine disruption can result in early mammary gland 
development, a common indicator of precocious puberty in girls, or gynecomastia, which is 
abnormal breast development in males. Both of these are associated with an increase in the 
risk of certain cancers developing later in life. Abnormal mammary gland development 
during lactation can lead to an inadequate production of milk. 
The most important potential disease outcome involving the mammary gland in 
humans is breast cancer. According to the American Cancer Society, in the United States, 
breast cancer develops in about 1 in 8 women and 1 in 1,000 men [7]. In women, breast 
cancer is the most commonly diagnosed form of cancer, and breast cancer breast cancer kills 
more women than any other type of reproductive cancer or endocrine-related cancer in the 
U.S. [8, 9]. Approximately 85% of breast cancers occur in women who have no family 
history of breast cancer [3]. 
Rodent studies have proven that the mammary gland is a sensitive tissue to the effects 
of EDCs, which are exogenous chemicals that, individually or in mixtures, may  interfere 
with any aspect of hormone action [10]. There are certain stages of development in which the 
mammary gland is more susceptible to the effects of EDCs. These “windows of 
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susceptibility” for the mammary gland are during embryogenesis, puberty and 
pregnancy/lactation; when the mammary gland is undergoing extensive proliferation. 
Terminal end buds (TEBs) are highly proliferative epithelial structures present during 
puberty in the rodent mammary gland. Since TEBs are the precursors of future branching 
ducts, damage or altered programming of these mammary gland structures can have lasting 
consequences within the structure of the mammary gland [6]. EDCs have been reported to 
change mammary gland development following prenatal, neonatal, and peripubertal exposure 
(reviewed in [6]). Chemical disruption of mammary gland development during the early 
windows of susceptibility (prenatal) can result in impaired lactation and altered susceptibility 
to cancer as adults. 
In addition to the developmental similarities, the cellular composition of human and 
rodent mammary glands is also similar. In humans, the functional portion of the mammary 
gland is called the terminal ductal lobular unit (TDLU) and in rodent species is it called the 
lobuloalveolar unit (LAU) or the terminal ends, not to be confused with TEBs. Both the 
TDLU and LAU are composed of similar luminal cuboidal epithelium and surrounding 
myoepithelial cells, with a tubuloalveolar morphology (abundant ducts and few alveoli) [11-
12]. During pregnancy and lactation, the mammary epithelium shifts to a lobuloalveolar 
morphology, with abundant alveolar lobules.  
The structure of mammary glands in men is considered a rudimentary form of the 
female gland [13]. On the other hand, mammary glands of rodents exhibit several sex-
associated structural differences. Male rats have branched mammary epithelium present at 
birth, though they have been reported to be smaller in size than those of females, and the 
mammary epithelium of sexually mature males have a permanent lobuloalveolar structure 
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[12]. Additionally, male mice may occasionally possess a residual stalk of epithelial tissue 
that is structurally similar to the female primary duct [14], and recent data suggests these 
stalks may respond to EDC exposure [15]. 
The rat mammary gland is an excellent model to study the effect of environmental 
chemicals that may impact breast cancer risk in humans [16]. Altered rodent mammary gland 
development during windows of susceptibility can be evaluated through the use of mammary 
gland whole mounts. Whole preparations of the mammary gland are fixed, defatted, stained 
and coverslipped with permount on a charged microscope slide. The glandular epithelial and 
stromal cells are stained with carmine and the outlines of adipocytes are intact. Whole 
mounts allow for evaluation of the total number and relative abundance of mammary gland 
ductal structures, including TEBs, overall growth of the epithelial cells, and branching 
density. [17].  
The current studies were performed to generate a pictorial atlas that characterizes 
mammary gland development in male and female Harland Sprague Dawley (HSD) rats. The 
study focuses on HSD rats as this strain is currently the rat of choice in some NTP test 
guideline studies.  Embryonic bud development was characterized histologically using fetal 
transverse hematoxylin and eosin (H&E)-stained sections starting on E15.5 and continuing 
through to E21.5. Postnatal development was evaluated using mammary gland whole 
mounts, coronal histology sections, and sex hormone receptor immunohistochemically 
(IHC)-stained sections prepared from the fourth and fifth inguinal gland starting at postnatal 
day (PND) 1 and continuing through to PND 70. To provide representative examples of 
accelerated or delayed mammary gland growth and differentiation in males and females, 
diethylstilbestrol (DES) or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (respectively) was 
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administered to a subset of pregnant dams during embryonic mammary gland organogenesis. 
This mammary gland atlas addresses male- and female-associated differences in both normal 
and chemically altered mammary development of HSD rats. The use of this atlas will benefit 
future studies assessing morphological changes in mammary gland endpoints in the HSD rat 
and other related strains.   
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Materials and Methods 
Animals  
Three blocks of timed-pregnant Sprague Dawley rats were purchased from Harlan 
Laboratories (Indianapolis, IN, USA). Pregnant dams arrived on GD 10 or 13 and were 
housed individually in polypropylene cages with bedding and nestlets and switched to a 
rodent phytoestrogen-reduced diet (Zeigler; Madison, WI). Water and chow were supplied ad 
libitum.  The animals were maintained in a room with a 12:12-hour light/dark cycle, at 20–
24 °C, and 40–50% relative humidity.  All animals were treated humanely and with regard 
for alleviation of potential suffering, as approved by the National Institute of Environmental 
Health Sciences Animal Care and Use Committee.   
Atlas Experiment 
Block One  
Timed-pregnant dams were randomly distributed among three treatment groups 
(n=9/group) with mean body weight (BW) being equivalent between the groups.  Dams in 
the three groups were treated by oral gavage on GD15 and GD18 with either 5 ml sesame 
oil/kg BW (vehicle control), TCDD (0.5 µg TCDD/kg BW), or DES (10 µg DES/kg BW). 
Dam BW was recorded daily throughout gestation. TCDD was purchased from Radian 
Corporation (Austin, Texas), and DES was purchased from Sigma (St. Louis, Missouri).  
Dosing solutions were prepared fresh on the days of treatment. The dose of DES was based 
on previous studies [18, 19] demonstrating no effects on prenatal loss or delayed parturition. 
The TCDD dose was derived from previous studies to avoid changing maternal weight gain, 
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but to give a dose to fetuses that may affect mammary development [17]. Treated and control 
dams were allowed to give birth and neonates were equalized to 10 pups per litter (5 male, 5 
female) on PND 4 to equalize growth potential across litters, minimizing litter effects. On 
PNDs 1, 4, 8, 12, 15, and 21, one dam and litter per treatment group were euthanized and 
mammary glands were collected from the dam and all pups for whole mounts and 
histology.  At PND 21, all remaining litters were weaned. Offspring (3 males and 3 females 
per litter) were sacrificed on PNDs 33, 46, and 70 to continue to monitor post-pubertal 
mammary gland development. 
Block Two 
Untreated timed-pregnant dams (n=14) were utilized for fetal mammary gland 
development. Two dams were sacrificed and male and female fetuses were collected (n=3 
fetuses/sex collected) for mammary gland evaluation on E15.5, 16.5, 17.5, 18.5, 19.5, 20.5 
and 21.5.  
Block Three 
Untreated timed-pregnant dams (n=8) were utilized for fetal mammary gland 
development. Two dams were sacrificed and male and female fetuses were collected (n=3 
fetuses/sex collected) for mammary gland evaluation on E18.5, 19.5, 20.5 and 21.5.  
Tissue Samples 
The fourth and fifth inguinal mammary glands are the easiest and largest glands to 
assess and were removed from both sides of the body, without the skin, in all dams and PND 
1- PND 70 pups from block one. One side was collected for whole mount and the other for 
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H&E or IHC. The samples for whole mount were fixed in Carnoy’s solution and stained in 
Carmine Alum as described in [17]. A male and female representative mammary gland was 
selected from each age group for pictorial representation. 
The fourth (and often fifth) gland on the contralateral side from the whole mounted 
gland was fixed in 10% neutral buffered formalin for 24 hours and transferred to 70% 
ethanol. Tissue samples were trimmed, processed and embedded in paraffin. Each block was 
step-sectioned until the lymph node was visible. After reaching the lymph node, four serial 5 
µm sections were collected for H&E and IHC staining. The following biomarkers were 
assessed by IHC staining: estrogen receptor alpha (ERα), progesterone receptor (PR), and 
androgen receptor (AR).  
Fetuses in blocks two and three were euthanized with wet ice and decapitation 
(E15.5-E 17.5) or by decapitation (E18.5-E21.5). In block two (n=14), fetuses were fixed in 
Bouin’s Fixative (Poly Scientific R&D Corp. Bay Shore, NY) for 48 hours. In block three 
(n=8), Bouin’s Fixative was injected into the abdominal cavity for better fixation and fetuses 
were further fixed in Bouin’s Fixative for 48 hours. Following fixation, a transverse cut was 
made at the level of the umbilicus. The upper half of the embryos was discarded while the 
bottom half was rinsed three times in 70% ethanol to remove the Bouin’s solution and placed 
in phosphate buffered saline at 4 °C.  Samples were then processed and embedded in 
paraffin. For optimal evaluation of the fetal mammary glands (E15.5- E21.5), the fetus was 
embedded in the transverse plane. The fetus was exhaustively sectioned (6 μm) through, in 
the region of the 4/5
th
 mammary gland. Fetal cross-sections that potentially contained 
mammary tissue were identified by light microscopy, then H&E stained.  
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ERα and PR immunohistochemistry 
Tissue sections were deparaffinized and rehydrated through a series of alcohols to 
phosphate buffered saline.  Endogenous peroxidase was blocked with 3% hydrogen peroxide.  
Heat induced antigen retrieval was performed using citrate buffer pH 6.0 (Biocare Medical, 
Concord, CA) at 120 °C for 5 minutes in a decloaking chamber (Biocare Medical).  The 
sections were incubated with 10% normal horse serum (Jackson Immunoresearch 
Laboratories, Inc., West Grove, PA) for 20 minutes. Endogenous biotin was quenched with 
the Avidin-Biotin Blocking Kit (Vector Laboratories, Burlingame, CA).  Sections were 
incubated with either anti-estrogen receptor alpha antibody at a 1:50 dilution (Beckman 
Coulter, Brea, CA; catalog # IM1545) or anti-progesterone receptor antibody at a 1:150 
dilution for 1 hour (Beckman Coulter, Brea, CA; catalog # IM1546). For a negative control, 
sections were incubated with mouse IgG1 isotype control serum in place of the primary 
antibody (BD Biosciences, San Diego, CA. Sections were incubated with the secondary 
antibody, horse anti-mouse secondary antibody (Vector Laboratories) for 30 minutes at 
1:1000 dilution and then labeled (Vector R.T.U. Vectastain Kit, Vector Laboratories) for 30 
minutes. The antigen-antibody complex was visualized following a 6-minute incubation with 
3, 3' diaminobenzidine (Dako Corporation, Carpinteria, CA). The sections were 
counterstained with modified Harris hematoxylin, dehydrated, cleared and coverslipped with 
Permount. 
AR immunohistochemistry 
Slides for AR IHC underwent deparaffinization, HIER and were blocked for 
endogenous peroxidase as described above. The sections were incubated with 10% normal 
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donkey serum for 20 minutes, followed by the Avidin-Biotin Blocking Kit (Vector 
Laboratories, Burlingame, CA) to quench endogenous biotin.  Rabbit polyclonal anti-
androgen receptor antibody (Santa Cruz Biotechnology, Dallas, TX; catalog # sc-816) was 
applied to the sections for staining at a dilution of 1:100 for 1 hour. Negative control slides 
received rabbit IgG serum at the same concentration as the primary antibody. A donkey anti-
rabbit biotin conjugated secondary antibody was applied for 30 minutes at a 1:500 dilution. 
Labeling, chromogen incubation, counterstaining and coverslipping were identical to the 
ERα and PR protocol described above. 
ERα/PR/AR quantification  
A modified Quick Score method [20] was used to report IHC staining for ERα, PR 
and AR in the mammary tissue. The overall intensity of the staining is scored on a scale of 0-
3; where 0= no staining/negative; 1= weak staining; 2= intermediate staining; 3=strong 
staining.  The estimated percentage of cells that are stained throughout the entire gland are 
scored on a scale of 1-6; where 1= 0-4% staining; 2= 5-19% staining; 3= 20-39% staining; 
4= 40-59% staining; 5= 60-79% staining; 6= 80-100% staining. The Quick Score is then 
calculated by multiplying the average intensity (0-3) by percent of cells stained (1-6). Quick 
scores range from 0-18 and only used for nuclear localized proteins. Nuclear staining was 
quantified by two reviewers unaware of the sample age, sex, or treatment group.   
Brightfield Slide Scanning 
Brightfield digital images were taken from slides scanned on an Aperio ScanScope 
XT™ instrument (Vista, CA) using ImageScope™ software (v9.0, Aperio). The extraction 
feature in Image-Scope™ was used if a digitally scanned image required rotation.  Image 
 
 
36 
 
enhancement (imaging, resizing and white balance correction) was done using Adobe 
Photoshop CC (Adobe Systems Incorporated, San Jose, CA, USA).  
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Results 
Harlan Sprague Dawley Rat Mammary Gland Atlas 
H&E fetal mammary bud development 
Sections of E15.5-21.5 fetuses from untreated dams demonstrate the progression of 
male and female mammary gland bud development (Fig. 2.1, 2.2, 2.3 and 2.4). At E15.5, the 
early mammary bud consists of a sphere of concentrically arranged epithelial cells subjacent 
to the plane of the surrounding epidermis (Fig. 2.1A-B and Fig. 2.3A-B). Cells surrounding 
the bud continue to elongate, condense and later connect to the skin surface by a stalk of 
epidermal-like cells at E16.5. During this gestational time point, the mature mammary bud 
surrounded by three to five layers of condensed mesenchyme, is referred to as the primary 
mammary mesenchyme. Developing from the mesenchyme, along with the formation of the 
ectodermally derived mammary buds, are the support structures including the adipose tissue, 
which later forms the fat pad containing blood vessels, lymphatics and connective tissue (Fig. 
2.1C-D and Fig. 2.3C-D). The bud remains quiescent from E16.5 to E17.5 and is relatively 
unchanged except for further progression into the underlying adipose tissue. At E18.5 in the 
male mammary gland, under the influence of androgens (testosterone) [21], the epithelial bud 
becomes separated from the epidermis as a result of apoptosis of the underlying mammary 
mesenchyme (Fig. 2.4). In the female, the mammary gland begins to invaginate where the 
nipple will develop (Fig. 2.2A-B). Invagination continues in the female until E19.5 when the 
outer structure of the nipple forms (Fig. 2.2C-D). At E20.5, the nipple sheath forms in the 
female rat (Fig. 2.2E-F). This is a modification of the skin present in the immediate vicinity 
of the mammary duct. The epidermis thickens and projects down into the dermis in an 
umbrella-like fashion, forming a ridge that surrounds the origin of the primary epithelial 
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duct. In contrast, the male mammary gland does not invaginate or undergo nipple formation. 
At E21.5, solid epidermal cords extend from the mammary bud and grow through the 
mammary mesenchyme into the secondary mammary mesenchyme, or fat pad precursor 
tissue, to form mammary sprouts in both the male and female (Fig. 2.2 G-H and Fig. 2.4 G-
H). Once the mammary sprout has reached the fat pad, it begins a process of ductal branching 
morphogenesis that gives rise to the rudimentary ductal tree, consisting of a primary duct and 
15-20 secondary branches, which is present at birth. 
Cellular morphology in pups and pregnant/lactating dam 
Cellular morphology of the female and male mammary gland can be 
compared/contrasted using H&E-stained longitudinal sections (Fig. 2.5 and 2.6, 
respectively). Although mammary gland development begins during gestation, the majority 
of development occurs after birth. Although samples were collected at seven ages, four age 
groups are presented in Fig. 2.5 and 2.6. These ages are often used for mammary gland 
comparisons in a variety of research studies; PND 4 (culls from litter size equilibration), 
PND 21 (extra weanlings), PND 46 (about the age chemical carcinogen is delivered), and 
PND 70 (young adult, similar to PND 90). At PND 4, both females and males displayed a 
simple mammary gland primarily composed of branching ducts and a few buds (Fig. 2.5A 
and 2.6A). Histologically, the ducts of the mammary gland of the pre-pubertal female and 
male rat are characterized by a single or double layer of cuboidal epithelium, which after 
branching a number of times and causing extension toward the lymph node, becomes 
multilayered to form the TEBs. These similarities in cellular structure continued through 
weaning (Fig. 2.5D and 2.6D). Around PND 21, the terminal end buds begin to cleave into 
clusters of three to five alveolar buds each with a centrally located lumen surrounded by a 
 
 
39 
 
layer of cuboidal epithelial cells. Between PND 21 and PND 46, the females will have 
undergone vaginal opening, begun regular hormone surges, and have an established estrous 
cycle [22]. The males are peri-pubertal at PND 46, likely progressing through preputial 
separation a few days prior to this timepoint [23]. By PND 46, there was an increase in the 
lobular architecture of the male gland.  Luminal epithelial cells contained enlarged vesicles 
within the lumens and by PND 70, the male mammary gland is a sexually mature gland. The 
glandular tissue is greater in volume and is organized into lobules of alveoli that consist of 
large, pale staining, foamy and vacuolated cells that are arranged around indistinct lumen that 
occasionally contain small amounts of eosinophilic secretory material. Ducts are lined by 
multiple layers of epithelium (pseudostratified or striated epithelium) and also have indistinct 
lumen and resemble alveoli. The mammary structure in the male is termed lobuloalveolar 
(Fig. 2.6J). At PND 70, the mammary gland of the mature, virgin female rat varies little 
histologically from that of a prepubertal female except for more abundant branching, 
narrower ducts, and more numerous alveolar buds and lobules. The female gland at this time 
point is characterized by branching tubular ducts, terminal end buds and alveolar buds, and 
clusters of patent alveoli are now tubuloaveolar structures (Fig. 2.5J).  
 
Mammary epithelium from DES-exposed females is similar in architectural 
appearance when compared to the controls at all time-points in H&E-stained sections. A 
tubuloaveolar structure is present with no appreciable difference in cellular structure or 
organization (Fig. 2.5B, E, H, and K). Mammary tissue from TCDD-exposed females 
contained significantly fewer terminal branches and alveoli when compared to controls and 
DES-exposed animals (Fig. 2.5C, F, I, and L). The TCDD induced delay of mammary gland 
development was persistent over time and was apparent at PND 21 and PND 46. However, 
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by PND 70 the mammary epithelium of TCDD-exposed females was more similar to age 
matched controls and DES-exposed females. 
The mammary epithelium of DES-exposed and control males were indistinguishable 
from each other from PND 4-46 (Fig. 2.6B, E, and H). At PND 70, when the control 
mammary glands became sexually mature, mammary tissue from DES-exposed animals 
contained typical lobuloalveolar structures centrally, matching the appearance of the control; 
however, the outer edges of the mammary gland maintained a tubuloalveolar structures 
characterized by a predominance of ducts and fewer alveoli (Fig. 2.6K). These findings may 
suggest that the DES-exposed males were feminized, or more likely, the mammary 
epithelium exhibited a delay in maturation. Similar to females, the mammary glands of 
TCDD-exposed males contained significantly fewer terminal branches and alveoli when 
compared to controls and DES-exposed animals (Fig.2.6C, F, and I). The TCDD induced 
delay of mammary gland development was persistent over time and was apparent at PND 4-
46. At PND 70, the mammary epithelium of TCDD-exposed males was more similar to age 
matched controls males (Fig. 2.6L).  
Sections of H&E-stained mammary glands from pregnant and lactating control dams are 
shown in Fig. 2.7. At GD 15, the mammary gland already had acquired a lobuloalveolar 
structure (large, vacuolated cytoplasm with a diminished lumen) with abundant adipose 
tissue (Fig. 2.7A). From GD 15 through GD 21, extensive ductal growth, lobular 
development, and alveolar maturation occurs to form milk-producing glands. With growth of 
the gland, there was a concurrent reduction in the amount of adipose tissue. (Fig.2.7B-C). 
The secretory alveoli became lined by low cuboidal epithelium, surrounded by a layer of 
myoepithelial cells, a basement membrane and a network of capillaries and lymphatics. The 
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continued growth of the mammary gland during pregnancy was due to increases in the height 
of the epithelial cells and expansion of the lumen of the alveoli. Lactation begins after the 
dam gives birth. Alveolar lumens were markedly expanded and distended with milk by PND 
4 (Fig. 2.7D). Since the mammary epithelial growth is quite extensive from late pregnancy to 
early lactation, it is difficult to distinguish ducts and adipose tissue on the mammary gland 
whole mounts due to the dramatic uptake of stain by the LA epithelium (data now shown). 
H&E-stained mammary sections are the best way to evaluate the late pregnant and lactating 
rat mammary gland.  
Differences in male and female ERα, PR and AR stained sections  
Nuclear ERα and PR in control male and female HSD rat mammary epithelia were 
not detectable at birth. In females at PND 8, no nuclear ERα staining was detected. However, 
faint cytoplasmic staining was present, which increased in amount and intensity at PND 33 
(Fig. 2.8A and B). At PND 70, the cytoplasmic staining was diminished (Fig. 2.8C). ERα 
was detected in epithelial nuclei as early as PND 21 in control females. Quick Score analysis 
revealed no significant difference in the amount of ERα positive nuclei in the mammary 
epithelium as the control animals progressed from weaning (PND 21) through adolescence 
(PND 33) to adulthood (PND 70). ERα positive nuclei were observed in mammary glands of 
DES-exposed females on PND 15, while expression was not detected in control mammary 
glands until PND 21. Some TCDD-exposed animals expressed ERα at PND 21(Fig. 2.10A). 
ERα was observed for the first time in mammary glands of the control, DES-exposed, and 
TCDD-exposed males at PND 33. After PND 33, ERα in male mammary glands was very 
low, if present at all (Fig.2.9A-C and Fig. 2.10B). 
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PR in the nuclei of control female mammary epithelium was first detected at PND 33 
and continued through PND 70. PR in mammary epithelium of DES-exposed female rats was 
first observed at PND 33, but was delayed in appearance in mammary epithelium of TCDD-
exposed females until PND 46 (Fig. 2.10E). PR was not present in male mammary 
epithelium at any time point or under any treatment condition (Fig.2.9D-F).   
Androgen receptor (AR) positively stained the nuclei in control male mammary 
epithelium as early as PND 4. Presence of AR was variable but continued to increase in both 
staining intensity and number of positively stained cells until about PND 46. By PND 70, AR 
nuclear receptor staining diminished to low levels in control males. While maximum AR 
stained mammary epithelium was observed at PND 45 in all males, the Quick Score was 
lower in glands of DES-exposed males compared to those of other males. Mammary glands 
of control males consistently exhibited slightly higher Quick Scores and more consistent AR 
stained mammary epithelium than glands of chemically exposed males (Fig. 2.10C and D). In 
females, positive nuclear AR stained mammary epithelium was variable and staining was 
very low throughout development when present (Fig. 2.8G-I and Fig. 2.9G-I). The Quick 
Score results are summarized over time, by sex, in Fig. 2.10.  
Whole mounts analysis of normal and chemically altered mammary gland development 
Normal and altered mammary gland development in both females and males was 
demonstrated with whole mounts (Fig. 2.11, 2.12 and Fig. 2.13, 2.14, respectively). At PND 
1, the mammary gland of an unexposed male and female HSD rat is composed of a primary 
duct and several branched secondary ducts. Mammary epithelium of the fourth gland had 
extended longitudinally to the lymph node and there were few alveolar buds present at birth 
 
 
43 
 
(Fig. 2.11A and Fig. 2.13A).  From about PND 4 to PND 21, alveolar buds increase in 
number until they have densely covered almost all the secondary ducts. Longitudinal 
epithelial growth has not extended past the lymph nodes and very few TEBs have formed. 
TEBs are the highly proliferative terminal ductal structures primarily responsible for 
epithelial extension through the fad pad. Between PND 21 and PND 33, there is a dramatic 
increase in the number of TEBs in both males and females. Longitudinal growth is rapid and 
the epithelium has grown past the lymph nodes; lateral growth has also increased and 
alveolar buds begin to form tertiary ducts (Fig. 2.12A and Fig. 2.14A). Also by PND 33, the 
fourth and fifth glands may have grown together (Fig. 2.12A and Fig. 2.14A). As puberty 
begins in the female around PND 34 [22], mammary epithelium proliferation accelerates 
quickly and by PND 46 and PND 70, growth continues to extend to the outer edges of the fat 
pad, TEBs have differentiated into terminal ends and the alveolar buds within the gland have 
become mature alveolar structures (Fig. 2.12D, G). 
Mammary glands developed similarly in both sexes before puberty. However, an 
unusual phenomenon was observed in males in that the fifth gland was not always present in 
this rat strain. The fifth mammary gland was missing in 50% of males (data not shown). 
Because of this phenomenon, only the fourth gland was evaluated in the male rats. 
Differences between the fourth mammary gland in male and female rats were not apparent 
until after PND 21 (Fig. 2.11A, D, G and Fig. 2.13A, D, G). After PND 21, the female 
mammary gland developed at a much faster and more uniform rate compared to those of 
males. By PND 33 in females, the mammary epithelium had grown past the lymph node, the 
fourth and fifth glands had grown together, and there was lateral growth to the edge of the fat 
pad. The number of TEBs had reached a maximum and terminal ends developed where the 
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gland had reached the edge of the fat pad. Compared to female glands, the male glands had 
reduced longitudinal and lateral growth and fewer TEBs. (Fig. 2.12A and Fig. 2.14A).  There 
was a greater degree of variability of mammary gland development among the male 
mammary glands after PND 21. Of the animals that had a fifth gland, not all had grown 
together at PND 33. These factors made selecting a representative image much more 
difficult. The epithelial area of male mammary glands changed little after PND 33, and in 
most glands did not ever reach the edges of the fat pad. In female mammary glands, TEBs 
begin to diminish as the gland reaches the end of the fat pad at PND 46, while in the males; 
TEBs differentiate into terminal ends prior to reaching the end of the fat pad (Fig. 2.12D and 
Fig. 2.14D). By PND 70, very few TEBs were found in the female mammary gland. (Fig. 
2.12G). The male mammary gland became very dense and exhibited the appearance of a 
sexually mature male mammary gland by PND 70, with prominent alveolar sacs and ducts 
that were barely visible (Fig. 2.14G).   
Comparing whole mount mammary glands from the DES-exposed females to the 
controls, the prepubescent females (PND 8-21) had dense and more abundant alveolar 
budding on the ducts (Fig. 2.11B, E, and H). TCDD-exposed females had very stunted 
mammary glands compared to controls. From PND 1-PND 21, the mammary glands of 
TCDD-exposed females exhibited consistently less branching and little alveolar budding off 
the ducts (Fig. 2.11C, F, and I). This is especially apparent in Fig. 2.11I. The fourth and fifth 
glands of both control and DES-exposed females had grown together by PND 33, while those 
of TCDD-exposed females had not (Fig. 2.12B-D). Despite having not grown together, there 
were still fewer TEBs present in the glands of TCDD-exposed females. The growth of the 
mammary epithelium in TCDD-exposed animals never caught up to that of the control 
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glands. By PND 70, mammary glands of TCDD-exposed females had not reached the end of 
the fat pad and there were more TEBs present than in controls (Fig. 2.12I). Differences 
between the treatment groups were more evident when compared by mammary whole mount 
vs H&E-stained section, likely because there was more information present on the slide to 
use in the tissue assessment.  
There was no marked difference in mammary gland size, branching/budding density 
or TEBs formation between the controls and DES-exposed male animals until PND 70, 
where the mammary epithelium typically continued to grow further through the fat pad than 
the mammary epithelium of the controls or TCDD-exposed males. The centers of the glands 
were dense, due to sexual maturation and conversion to a lubuloalveolar epithelial structure, 
but the outer edges were less dense, like a female or immature gland, similar to what was 
found in the H&E stained glands (Fig. 2.13B, E, and H, and Fig. 2.14B, E, and H). The 
mammary epithelium of TCDD-exposed males was underdeveloped compared to the 
controls. In the prepubescent males (PND 1-21), there was less budding off the ducts 
compared to the controls (Fig. 2.13C, F, and I). The longitudinal and lateral growth of the 
mammary epithelium of the TCDD-exposed males caught up to the controls by PND 33 (Fig. 
2.14C). Further mammary epithelium expansion was minimal and the whole mounts of the 
TCDD-exposed males appeared similar to the controls in terms of size and density through to 
PND 70 (Fig. 2.14F- I). 
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Compiled literary findings on the progression of mammary gland development and 
hormones levels in female rats. 
Fig. 2.15 is a compiled literary search on what is currently known about female rat 
mammary gland development, receptors present in the mammary gland and sex hormone 
levels throughout the life span (mostly in Charles River Sprague Dawley rat). Data from our 
studies has been added to the figure (the Developmental Effects and Receptor Expression for 
ERα, PR and AR) to fill in data gaps. 
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Summary 
The NTP has moved away from the use of the inbred Fisher 344/N rat due to 
decreased fecundity, sporadic seizures and high rates of mononuclear cell leukemia and 
testicular neoplasia [24]. One of the preferred testing strains is now the HSD rat because the 
litter size, sex ratio, and body weights were favorable [25]. Guideline studies (modified one 
generation reproduction studies, reproductive assessment by continuous breeding studies and 
2-year bioassays) have been modified to include assessing mammary gland development in 
their standard testing protocols [26]. Since the majority of current studies in the literature are 
based on the Charles River Sprague Dawley strain and strain differences in mammary gland 
development have not been documented, it was important to make an atlas of normal HSD 
rat mammary gland development. Additionally, a comparison of normal and chemically 
altered mammary glands would fill data gaps in HSD mammary gland development. This 
atlas compares the growth and timing of critical mammary gland events starting at mammary 
gland bud formation and continuing through sexual maturity. We confirmed that the female 
mammary gland undergoes similar stages of development as has been previously shown in 
other rat strains [16, 27-29] and that the male mammary gland is structurally and 
morphologically similar to that of the females up until the onset of puberty. The HSD female 
mammary epithelium proliferates and spreads through the fat pad much faster compared to 
other strains (Stanko J, personal communication, January 22, 2015). By PND 33, 100% of 
the fourth and fifth mammary glands in the control females had already grown together (data 
not shown). This event does not occur until around PND 45 in other strains, such as Charles 
River Sprague Dawley (Stanko J, personal communication, January 22, 2015) and Long 
Evans rats [27]. This information is vital for future carcinogen-induced mammary tumor 
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model studies in rats, as the HSD female rat may have a smaller window of susceptibility to 
mammary carcinogens, compared to other rat strains. As a result, the HSD rat may be less 
susceptible to EDCs effects on mammary gland development than other strains. 
The adult female rat mammary gland has been extensively studied but developmental 
time points are less understood. The atlas developed within these studies, adds or confirms 
important information on the development and timing of the mammary glands of male and 
female HSD rats. The female mammary gland that is undergoing lactation or involution has 
been well documented (Fig. 2.7), but embryogenesis and puberty are other critical windows 
of susceptibility that deserve more attention. The developmental events in Fig. 2.15 were 
demonstrated in the female HSD rat in the atlas. The mammary gland bud developed by 
E15.5 and epithelial ducts with a lumen were present at birth and continued to rapidly expand 
through to adulthood. TEBs began to form just before puberty and differentiated into mature 
lobules once reaching the end of the fat pad or other mammary glands at the beginning of 
adulthood. Chemically exposed HSD female rats showed expected and unexpected results. 
The TCDD model of stunted mammary gland growth in rats showed expected results [17]. 
The mammary gland was smaller and developmentally delayed compared to the control 
starting at PND 8 and never fully recovered by PND 70. The model for accelerated growth, 
with DES did not result in noticeably accelerated mammary gland development in the 
female. However, feminization may have occurred in the males exposed to DES in utero. 
This strain of rat may not be as sensitive to DES treatment as other strains, especially when 
considering that the HSD already exhibits accelerated mammary gland development 
compared to other strains (Stanko J, personal communication, January 22, 2015). During 
windows of susceptibility, hormone disruption, changes in receptor population in mammary 
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glands or altered mammary gland development can result in later life effects, including 
impaired lactation and breast cancer development [6]. Since the mammary gland is such a 
dynamic organ and is sensitive to various perturbations, it is critical to know both what is 
normal and what changes early in life will result in adverse outcomes later in life.   
The steroid hormone receptors, estrogen and progesterone, have also been extensively 
studied in the adult mammary gland [30-33] and their presence or absence is shown in Fig. 
2.15. The androgen and protein receptors were less well defined in the mammary gland and 
there are currently data gaps in the neonatal and peripubertal time points for some of these 
receptors. The ERα, PR and AR staining performed in these studies added information to Fig. 
2.15. The findings in this study agree with previously published ERα data [34] in female 
Sprague Dawley rats in that no nuclear staining was observed until PND 21 in the controls. 
PR was not found in neonatal females but as previously reported in other strains [35] it is 
present in prepubertal and adult females. AR staining data added new information to the 
table, demonstrating that AR was not present in mammary epithelium nuclei until PND 15 in 
female controls, and only very low expression through PND 70. DES-exposed animals were 
the only group to have nuclear ERα present at PND 15 and TCDD delayed the presence of 
PR until PND 46. AR expression was very low in females and often variable, but DES-
exposed animals very rarely had any expression at any time point. The male ERα, PR and 
AR staining data elucidates the differences and similarities between males and females 
during key moments of mammary gland development that previously have not been studied. 
Differences in steroid hormone receptor populations give insight into when EDCs would 
have their maximal effect on the mammary gland. ERα expression, while had very low 
overall expression levels in males, was present by PND 33, which is over a week later than it 
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is seen in females. PR expression was not detectable in the male mammary glands. AR 
expression was much higher in male mammary glands compared to females, and peaked at 
PND 46. DES treatment reduced the amount of AR expression at PND 46 compared to other 
treatments. The ranges of normal circulating serum hormone levels of nulliparous female rats 
starting at puberty and through adulthood are presented in Fig. 2.15. 
The male rat mammary gland has not been extensively studied. The male mammary 
gland is structurally similar to the females up until puberty. While both glands grow 
exponentially, the male mammary gland grows at a slower rate than the females starting at 
PND 33 and stops growing in overall area after about PND 45, which coincides with the 
timing of male puberty and increased serum testosterone levels [36]. The female mammary 
epithelium continues to extend until it reaches the end of the fat pad, while the male 
mammary gland stops growing before then, most likely due to the animal reaching sexual 
maturity and increased levels of testosterone. Once the male reaches sexual maturity there is 
a structural change of the mammary gland from a tubuloalveolar to a lobuloalveolar 
structure, which has been previously described, but the precise mechanism for the shift in 
morphology is unknown [12, 37]. As expected the TCDD-exposed animals had 
developmentally delayed mammary gland growth before puberty, but seemed to catch up to 
controls by young adulthood. The DES-exposed animals did not exhibit accelerated 
mammary gland development compared to the controls. A different amount of DES or 
different DES exposure paradigm may be needed for an appreciable accelerated mammary 
gland development.  
 It is hoped that this atlas will enhance the ability of chemical screening and testing 
labs to produce and evaluate mammary gland sections or whole mounts from male and 
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female offspring in their studies. This atlas can be used as a reference for histological and 
gross changes that may occur in the situation of delayed or accelerated development.  It may 
also provide useful information on mode of action for chemicals that shift steroid hormone 
receptor nuclear localization patterns. In order to prevent breast cancer in men and women 
and precocious breast development in girls around the globe, we must first understand some 
of the environmental factors adversely affecting the breast.  Further evaluation of the male 
and female mammary gland in screening and test guideline studies will help produce the data 
needed to move this process forward.     
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Figure 2.1. Representative H&E images of female HSD rat fetal mammary gland 
development E15.5-17.5. (A and B) Mammary bud formation, E15.5 (A) 16X. (B) 40X. (C 
and D) Mammary stalk formation, E16.5 (C) 16X. (D) Mesenchymal layer forms (arrow) 
40X. (E and F) Elongation of mammary stalk, E17.5. (E) 16X. (F) 40X.  
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Figure 2.2 Representative H&E images of female HSD rat fetal mammary gland 
development E18.5-21.5. (A and B) Invagination of the skin above the mammary gland, 
E18.5. (A) 16X. (B) 40X. (C and D) Elongation of the mammary gland, E19.5. (C) 16X. (D) 
40X. (E and F) Formation of the nipple sheath, E20.5. (E) 16X. (F) Nipple sheath forms 
(arrow) 40X. (G and H) Primary duct begins lumen formation, E21.5 (G) 16X. (H) 40X.  
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Figure 2.3 Representative H&E images of male HSD rat fetal mammary gland 
development E15.5-17.5. (A and B) Mammary bud formation, E15.5 (A) 16X. (B) 40X. (C 
and D) Mammary stalk formation, E16.5 (C) 16X. (D) Mesenchymal layer forms (arrow) 
40X. (E and F) Elongation of mammary stalk, E17.5. (E) 16X. (F) 40X.  
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Figure 2.4 Representative H&E images of male HSD rat fetal mammary gland 
development E18.5-21.5. (A and B) Atrophy of the mammary gland stalk, E18.5. (A) 16X. 
(B) 40X. (C and D) Further atrophy of the mammary gland stalk, E19.5. (C) 16X. (D) 40X. 
(E and F) Primary duct begins lumen formation, E20.5. (E) 16X. (F) 30X. (G and H) 
Elongation of the primary duct, E21.5. (G) 16X. (H) 40X. 
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Figure 2.5 H&E Images of female mammary gland development in control and 
gestationally exposed HSD rat offspring from birth to sexual maturity. (A-C) Mammary 
gland sections of neonatal rats on PND 4, 10X. (A) Control, (B) DES, and (C) TCDD-
exposed. (D-F) Mammary gland sections of prepubertal rats on PND 21, 10X. (D) Control, 
(E) DES, and (F) TCDD-exposed. (G-I) Mammary gland sections of peripubertal rats on 
PND 46, 10X. (G) Control, (H) DES, and (I) TCDD-exposed. (J-L) Mammary gland sections 
of sexually mature rats on PND 70,10X. (J) Control, (K) DES, and (L) TCDD-exposed. 
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Figure 2.6 H&E Images of male mammary gland development in control and 
gestationally exposed HSD rat offspring from birth to sexual maturity. (A-C) Mammary 
gland sections of neonatal rats on PND 4, 10X.  (A) Control, (B) DES, and (C) TCDD-
exposed. (D-F) Mammary gland sections of prepubertal rats on PND 21, 10X.  (D) Control (, 
(E) DES, and (F) TCDD-exposed. (G-I) Mammary gland sections of peripubertal rats on 
PND 46, 10X.  (G) Control, (H) DES, and (I) TCDD-exposed.  (J-M) Mammary gland 
sections of sexually mature rats change to a lobuloalveolar epithelial structure on PND 70, 
10X. (J) Control, (K) DES lobuloalveolar structures (left) and remnant tubuloavleolar 
structures at the edge of the tissue (right), and (L) TCDD-exposed.  
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Figure 2.7 H&E-stained sections of HSD dam mammary gland during pregnancy and 
lactation. Control mammary glands during pregnancy and lactation (A) GD 15, (B) GD 17, 
(C) GD 21 and (D) PND 4. 20X. 
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Figure 2.8 ERα, PR and AR immunohistochemistry staining of control female 
mammary gland development. (A-C) ERα, (D-F) PR, and (G-I) AR. (A, D and G) PND 8, 
(B, E, and H) PND 33, and (C, F, and I) PND 70. 20X. There was nonspecific staining of the 
mast cells, not a part of the mammary gland epithelium. 
 
 
 
 
 
 
 
60 
 
 
Figure 2.9 ERα, PR and AR immunohistochemistry staining of control male mammary 
gland development. (A-C) ERα, (D-F) PR, and (G-I) AR. (A, D and G) PND 8, (B, E, and 
H) PND 33, and (C, F, and I) PND 70. 20X. There was nonspecific staining of the mast cells, 
not a part of the mammary gland epithelium. 
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Figure 2.10 ERα, PR and AR Quick Score of female and male offspring mammary 
glands. (A-B) (A) Nuclear ERα first appeared at PND 15 in the DES-exposed females and 
PND 21 in control and TCDD-exposed females. (B) Nuclear ERα first appeared at PND 33 
in the males. (C) There was very little AR staining in the females and was sporadic in the 
chemically exposed animals and more consistent in the control females. (D) AR stained male 
glands at low levels until puberty in control and TCDD-exposed animals. DES had a less 
intense nuclear staining. (E) PR was only expressed in the females and first appeared at PND 
33 in Control and DES-exposed animals, and PND 46 in TCDD-exposed animals. (n=2-3). 
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Figure 2.11 Whole mount female mammary gland developmental progression of control 
and prenatally exposed HSD offspring from birth to pre-puberty. Representative 
carmine stained mammary gland whole mount images of (A-C) neonatal rats on PND 1, 4X, 
(A) Control, (B) DES, and (C) TCDD-exposed; (D-F) neonatal rats on PND 8, 2X (D) 
Control, (E) DES, and (F) TCDD-exposed; (G-I) prepubertal rats on PND 21, 2X (G) 
Control, (H) DES, and (I) TCDD-exposed. 
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Figure 2.12 Whole mount female mammary gland developmental progression of control 
and prenatally exposed HSD offspring from puberty to sexual maturity. Representative 
carmine stained mammary gland whole mount images of (A-C) pubertal  rats on PND 33, 
0.8X, (A) Control, (B) DES, and (C) TCDD-exposed; (D-F) peri-pubertal rats on PND 46, 
2X (D) Control, (E) DES, and (F) TCDD-exposed; and (G-I) adult rats on PND 70, 2X (G) 
Control, (H) DES, and (I) TCDD-exposed. 
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Figure 2.13 Whole mount male mammary gland developmental progression of control 
and prenatally exposed HSD offspring from birth to pre-puberty. Representative 
carmine stained mammary gland whole mount images of (A-C) neonatal rats on PND 1, 4X, 
(A) Control, (B) DES, and (C) TCDD-exposed; (D-F) neonatal rats on PND 8, 2X (D) 
Control, (E) DES, and (F) TCDD-exposed;  and (G-I) prepubertal rats on PND 21, 2X (G) 
Control, (H) DES, and (I) TCDD-exposed. 
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Figure 2.14 Whole mount male mammary gland developmental progression of control 
and prenatally exposed HSD offspring from puberty to sexual maturity. Representative 
carmine stained mammary gland whole mount images of (A-C) prepubertal  rats on PND 33, 
0.8X, (A) Control, (B) DES, and (C) TCDD-exposed; (D-F) pubertal rats on PND 46, 2X (D) 
Control, (E) DES, and (F) TCDD-exposed; and (G-I) adult rats on PND 70, 2X (G) Control, 
(H) DES, and (I) TCDD-exposed. 
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Figure 2.15 Compiled literary data on the Charles River Sprague Dawley female rat. 
The developmental events, receptor expression of the mammary gland and the hormone 
levels in the serum of female rats, from neonates to adults. 1 (Emanuele et al. 2001).  2 
(Biegel et al. 1998).  3 (Kim et al. 2002).  4 (Saji et al. 2000). 5 (Kariagina et al. 2008). 6 
(Miousse et al. 2013). 7 (Cheung et al. 2001). 8 (Cotroneo et al. 2002). 9  (Tan et al. 2004). 
10 (Thordarson et al. 1995). 11(Hvid et al. 2011). 12(Kao et al. 2000). 13(Dohler and Wuttke 
1975). 14(Severino et al. 2004). 15(Eccles 2011). 16(Darcy et al. 1999). 17 (Weisz and Ward 
1980). 18  (Wilson and Handa 1997). 19  (Frawley and Henricks 1979). 20 (Devaskar et al. 
1997). 
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CHAPTER 3: VOC body burdens in rat mothers and offspring following drinking 
water exposures to a human relevant VOC mixture during pregnancy and adolescence 
Introduction 
Volatile organic compounds (VOCs) are common groundwater contaminates in many 
Superfund sites [1-5]. Superfund is the federal program to clean up uncontrolled hazardous 
waste sites in the U.S. and is committed to cleaning up hazardous waste sites to protect the 
environment and the health of local populations. VOCs will quickly off-gas from surface 
water but demonstrate a long half-life if they make their way into ground water. VOC 
contaminated groundwater used for human activities (bathing, cooking, watering plants, etc.) 
or consumption, can expose a population through inhalation, ingestion and dermal 
absorption. After exposure, VOCs are quickly eliminated from the body, as they have a short 
half-life in humans [1-5]. Populations near emission sources or contaminated drinking water 
could have elevated VOC serum levels in the low ppm range [1-6]. One example of 
accidental exposures to VOCs occurred on a Marine base in Jacksonville, NC, where VOCs 
contaminated some of the drinking water wells from the 1950’s to the 1980’s before the 
problem was identified and remediated. Hundreds of service people have complained of 
adverse health outcomes that they believed were linked to their VOC exposures [7]. Of the 
VOCs identified in the well water, benzene, vinyl chloride (VC) and trichloroethylene (TCE) 
are known human carcinogens, and tetrachloroethylene (PERC) is reasonably anticipated to 
be carcinogenic to humans [8-12].  
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In addition to the effects of the parent compounds, these VOCs are metabolized in the 
liver to form compounds known to be toxic [1-5]. The liver is an important organ as it 
functions to metabolize and detoxify many compounds. While some VOCs are eliminated by 
exhaling unconjugated forms (about 80% of PERC, 40% of benzene 10% of TCE and 5% of 
VC) , extensive animals studies have revealed that VOCs are metabolized by phase one 
cytochrome P-450 (CYP) metabolism and phase two conjugation in the liver or kidneys. 
Benzene, PERC, TCE, trans-1,2-Dichloroethylene (trans-1,2-DCE) and VC are primarily 
metabolized by Cyp2e1. The many metabolic pathways for benzene are outlined by the 
Agency for Toxic Substances and Disease Registry (ATSDR) in their Toxicological Profile 
for Benzene. Cyp2e1 metabolism can result in the formation of the reactive metabolites 1,2- 
and 1,4-benzoquinone [1]. The concentrations of the individual metabolites of benzene are 
dependent on both the dose amount and route of exposure[13]. The toxicity of low-dose 
exposures to benzene may be underestimated by high-dose exposures. 
TCE is metabolized by both CYP oxidation and glutathione (GSH) conjugation by 
GSH-tranferase [3]. Cyp2e1 is the major CYP responsible for the metabolism of TCE, but 
others (e.g., Cyp1a1/2, Cyp2b1/2 and Cyp2c11/6) can oxidize TCE when Cyp2e1 is not 
functional, as has been demonstrated using a knock-out Cyp2e1 mouse model [14]. TCE 
metabolite, trichloroacetic acid (TCA) modifies signaling pathways (peroxisome 
proliferation) resulting in cell death and reparative hyperplasia. Subsequent somatic 
mutations are thought to lead to liver toxicity and carcinogenesis [15]. The second pathway 
of TCE metabolism, GSH conjugation, produces S-dichlorovinyl-glutathione isomers that 
can be transported to the kidney and metabolized to S-dichlorovinylcysteine isomers. Both 
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types of isomers are mutagenic, transported to the kidneys, and play a significant role in the 
mutagenic mode of action in TCE-induced kidney tumors [8]. 
Both trans-1,2-DCE and cis-1,2-DCE are metabolized primarily by Cyp2e1 in the 
liver. Dichloroacetic acid (DCA) and 2,2-dichloroethanol are the major metabolites found 
after trans-1,2-DCE exposure and can be found in the urine [16]. The further metabolism of 
2,2-dichloroethanol or DCA has not been investigated in the context of trans-1,2-DCE 
metabolism. However, it is known that the metabolites of trans-1,2-DCE do not undergo 
GSH conjugation[12, 16-17]. Exposure to trans-1,2-DCE does not elevate liver enzymes in 
rodents and it is not genotoxic [12]. The literature on rodents suggests that the liver is the 
organ most affected (fatty accumulation of liver lobules and Kupffer cells) by exposure to 
trans-1,2-DCE at high doses, but lacks evidence of any specific pathological event[12]. 
PERC is metabolized through two irreversible pathways: oxidation by 
Cyp2e1/Cyp2b1 and GSH conjugation via GSH-transferase [2, 10]. Oxidation of PERC can 
result in generation of the toxic metabolites TCA and dichloroacetic acid (DCA). As seen in 
TCE treated animals, liver cytotoxicity and carcinogenesis have been associated primarily 
with the metabolite TCA, while DCA may also play a role [18-19]. GSH conjugation of 
PERC primarily occurs in the liver and kidneys. Reactive metabolites in the kidneys 
produced via the glutathione conjugation pathway may play a role in the renal toxicity and 
carcinogenicity in PERC exposed rats [2, 10]. 
As stated in Chapter 1, previous testing of VOCs has primarily focused on high dose 
exposures to one chemical at a time in adult animals, a testing paradigm that may mask 
mammary gland effects. The goal of these studies were to better understand how VOCs 
behave under more human relevant conditions; namely as a mixture, in susceptible 
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subpopulations and through a drinking water exposure route. VOCs were mixed in sesame 
seed oil at ratios similar to well water at Camp Lejeune and then given as a single gavage 
dose to pregnant rats. Blood, mammary gland and a fetus were collected over 24 hours to 
access the half-lives of the VOCs in each of the three tissues. To determine how the VOCs 
would accumulate over time with an episodic VOC exposure in pregnant and adolescent rats, 
drinking water was given containing VOCs at concentrations 5-50 times higher than those 
reported at Camp Lejeune. The studies in Chapter 2 revealed the details of  mammary gland 
development in male and female HSD rats. The studies in this chapter will determine the 
body burden complexities of VOCs when given as mixture, via drinking water exposure, in 
the pregnant/lactating HSD dam and her offspring.  
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Materials and Methods 
Animals 
Time pregnant Sprague Dawley rats were obtained from Harlan Laboratories (HSD; 
Indianapolis, IN) on gestational day (GD) 13 and allowed to acclimate for 2 days. Animals 
were weighed upon arrival and separated into groups with a similar average weight. Pregnant 
dams were housed individually in polypropylene cages with bedding and nestlets and 
switched to a rodent phytoestrogen-reduced diet (Zeigler; Madison, WI). Water and chow 
were supplied ad libitum. Animal facilities were maintained on a 12:12 h light-dark cycle at 
20°C–23°C and 40–50% relative humidity. All animal studies were approved by the NIEHS 
Animal Care and Use Committee. 
Chemicals 
Chemical stock solutions for gavage dosing were purchased from Sigma Aldrich, 
(Steinhiem, Switzerland) and included; Benzene (0.874g/mL), PERC (1.622g/mL), TCE 
(1.463g/mL), DCE (1.252g/mL) and VC (2.0 g/mL). For the drinking water study, 1 ml 
ampules containing a concentrated standard mixture of benzene, PERC, TCE and trans-1,2-
DCE were purchased by the Centers for Disease Control and Prevention (CDC) from O2si 
(Charleston, SC) and VC (2000µg/ml) was purchased from Sigma Aldrich (Steinhiem, 
Switzerland). The measured level of VOCs in the well water at Camp Lejeune [20] was 
denoted as 1 X: 1.5ppm PERC, 0.2ppm TCE, 0.4ppm trans-1,2-DCE, 0.025ppm VC and 
0.2ppm benzene. VOC drinking water solutions for this study were prepared by spiking 
38.85 µl of the mixture standard and 312.5 µl of VC into 500 ml deionized/reverse osmosis 
water resulting in 10 µg/ml of benzene, 75 µg/ml of PERC, 10 µg/ml of TCE, 20 µg/ml of 
trans-1,2-DCE and 1.25 µg/ml of VC for the “50X” or 50 times the well water VOC 
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concentrations. Serial dilutions were made for “10X” and “5X” concentrations (Table 3.1). 
500 ml glass drinking water bottles with metal sippers were filled with dosed drinking water 
and given to animals to drink ad libitum. Pilot experiments showed that VOC off-gassing 
depended on the amount of head space in the water bottle more so than the length of time 
since freshly mixed (data not shown). The drinking water bottles were changed at least every 
other day to ensure no more than 25% of the water was consumed before changing the water, 
to reduce variation in VOC water concentration. 
Experimental Design 
Two animal studies were conducted with the mixture of VOCs. 
1. Half-life of a mixture of VOCs in the pregnant dam: Time pregnant HSD rats 
(18 dams) arrived at the NIEHS on GD 13 (GD 0=plug positive). On GD 15 each 
animal (except one non-treated control) was gavage dosed with a mixture of 
VOCs at 0.25mg/kg VC, 20mg/kg benzene, 20mg/kg PERC, 40mg/kg DCE and 
150mg/kg TCE at a volume of 5 mL/kg body weight in sesame oil (Table 3.1). 
Rats were weighed just prior to dosing. High doses were selected to insure half-
lives could be estimated and the ratio of chemicals given were based on well 
water at Camp Lejeune. 
2. Body burden from VOCs in drinking water: Timed-pregnant HSD rats (68 
dams) arrived on GD 10, were switched to a low soy Purina Lab Diet 5008 chow 
and were divided into 4 treatment groups (n=13, 18, 17 and 19 in Control, 5X, 
10X and 50X VOC dose groups, respectively). All dams and pups were given 
glass water bottles containing concentrations of the VOC mixture (0, 5X, 10X or 
50X VOC concentrations, see Table 3.1) from GD 12 through PND 48 from 
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which they could drink ad libitum. Pups began drinking water exposure on PND 
13 (once their eyes opened). Dams were allowed to give birth and litters were 
equalized on PND 4 to 5 female and 5 male offspring. Drinking water exposure 
continued for dams and pups until sacrifice.  
Necropsy 
1. Half-life of a mixture of VOCs in the pregnant dam: Two dams per time point 
were sacrificed by CO2 affixation at 0, 15mins, 30mins, 2 hrs, 4hrs, 8hrs, 16hrs 
and 24hrs after gavage with VOC mixture. Dams were sacrificed for VOC blood 
concentration. To evaluate the amount of VOC present in the blood it was 
important to prevent any off-gassing of VOC when collecting the blood and to 
prevent potential VOC contamination. Tubes, stoppers and syringes were 
provided by the CDC to insure there were no trace VOC residues. The rats were 
sedated and a terminal cardiac puncture was performed. The blood was collected 
directly into blood collection tubes so that it was not exposed to the room air. A 
section of the 4
th
 mammary gland and one intact fetus were also collected and 
placed in separate blood collection tubes. After collection, samples were 
refrigerated and then shipped cold with freezer packs, but not frozen, by overnight 
delivery to CDC laboratories in Atlanta, GA for analysis. 
2. Body burden from VOCs in drinking water: Three dams from each dose group 
were sacrificed on GD 15, GD 17, GD 20, PND 15 and PND 21 by CO2 
affixation. Three female and three male pups from each dose group were 
sacrificed on PND 15, 21, 28 and 48 by CO2 affixation. Blood was collected and 
shipped to the CDC in a similar fashion as the half-life study. For an initial 
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analysis, the blood of dams (GD13-21) in the control, 5X and 10X dose groups 
were tested. It was determined that the 5X group was too close to the lower limit 
of detection, so for the rest of the blood (dams PND 15, 21 and pups PND 15, 21, 
28, 48) only 10X and 50X were tested.  Body weights and liver weights were 
recorded. For necropsies on the offspring, after the blood was obtained, one set of 
4
th
 and 5
th
 mammary glands were removed for whole mount analysis and the 
contralateral set was collected, placed in histology cassettes and fixed in formalin 
for IHC processing. A section of liver and mammary gland were snap frozen for 
RNA analysis. 
Headspace solid-phase microextraction with benchtop gas chromatography–mass 
spectrometry 
 To quantify levels of VOCs, blood samples were measured by headspace solid-phase 
microextraction (SPME)/gas chromatography (GC)/isotope dilution mass spectrometry (MS) 
using similar methods as described by Blount, et al.[21] and Chambers, et al.[22]. Analysis 
of the blood sample was performed by equilibrium headspace analysis using SPME. For 
analysis, 3-ml of blood was transferred by gas-tight syringe from a blood collection tube to a 
headspace vial. The SPME fiber shaft was inserted into the headspace of a hermetically 
sealed sample vial containing the blood sample. The VOCs partitioned into the coating on the 
outside of the SPME fiber shaft. This fiber was then inserted into the heated GC inlet where 
the VOCs rapidly desorbed because of the high temperature. Extracted VOCs were focused 
at the head of the GC column using a cryogenic trap. Analytes were separated on a capillary 
column designed for VOC analyses and quantified using MS (unit mass resolution). 
Response calibration was performed using standards to normalize calibration standards and 
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blood sample response. This method is applicable to the determination of a broad range of 
VOCs with detection limits in the low-parts-per-trillion range. Similar methods were used to 
analyze fetal and mammary gland tissues. The detection limits achieved with this method 
were 5, 24, 5, and 8 pg/ml for trans-1,2-DCE, benzene, TCE, and PERC,  respectively. 
Quantitative Polymerase Chain Reaction 
Frozen liver samples from male offspring were homogenized by MP FastPrep-24 
homogenizer using lysing matrix D (MP Biomedicals, Solon, OH) in TRIzol (Life 
Technologies Inc, Rockville, MD) and RNA was isolated according to TRIzol 
manufacturer’s protocol. Total RNA was cleaned-up using Qiagen RNeasy Mini Kit with the 
addition of On-Column DNase digestion (Qiagen; Hilen, Germany) according to 
manufacturer’s instructions. Total RNA was quantified using NanoDrop 2000c 
(ThermoScientific, Wilmington, DE). Taqman (Applied Biosystems, Branchburg, NJ) assays 
were purchased for Cyp2e1, Cyp2b1 and Actb. Approximately 2μg RNA was reverse 
transcribed using the Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, CA). 50 ng 
of cDNA was run in duplicate on QuantStudio 7 Flex Real Time Instrument (Applied 
Biosystems). Cycle Threshold (Ct) values were calculated using QuantStudio Real Time 
Software and were included in the analysis if the standard error for the duplicates were ≤0.5.  
The ΔCt was calculated for each transcript by normalizing the sample Ct values by the Ct 
values of Actb transcript in the same sample. For VOC treatment effect, the relative gene 
expression was calculated by dividing the mean 2-Δct of treated samples over the mean 2-Δct 
of the control. For CYP changes over time, the relative gene expression was calculated by 
dividing the mean 2-Δct of PND 21, 28 and 48 samples over the mean 2-Δct of the PND 14 
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samples. For relative gene expression that was between zero and one, the negative inverse 
was used to represent fold change.  
Estimation of rates of elimination and half-life calculations of VOCs  
Rates of elimination of VOCs were estimated as described in Troester et al. (2000) 
[23]. Following a single dose of VOC mixture, individual chemicals were estimated to be 
eliminated by first-order kinetics according to the following expression: 
[𝐴]𝑡 = [𝐴]0𝑒
−𝜆𝑡 
Where A0
 is the chemical concentration at t= 0 and λ (d-1) is the first-order rate constant for 
each chemical’s elimination. From the above equation, the relationship between ln[A(t)] and 
t is linear with intercept = ln(A0) and slope = -λ, that is,  
𝑙𝑛[𝐴]𝑡 = 𝑙𝑛[𝐴]0 − 𝜆𝑡 
And λ can be estimated by linear regression of ln A(t) on t. Half-lives (𝑡1
2
) of each chemical 
were then determined by the following equation: 
𝑡1
2
=
0.693
𝜆
 
To determine λ, first peak concentration was determined. Then time of collection (t) was 
transformed into time from peak concentration (t'). The concentrations (conc) were 
transformed into the ln[conc]. In Excel, the coordinates of t' and the ln[conc] of each time 
point from peak concentration were plotted on a graph and a line was fitted to the resulting 
coordinates. The slope of the fitted line was –λ and was entered into the above question for 
𝑡1
2
. 
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Percent daily dose per gram tissue estimations for 10X dams 
 Direct comparisons between the amounts of each VOC in the blood was not possible, 
since the concentrations of each VOC in the drinking water were different. Measuring the 
amount of water consumed during the study was also not possible because once born the 
animals were grouped house for the duration of the study. Since direct calculations of 
average daily doses were not possible, an estimated average daily dose was used instead. The 
assumption was made that for each day of pregnancy, average water consumption would 
result in an average daily dose of 1/8th the VOC concentration in the water, and during 
lactation it was 1/5th. The estimated average dose (mg/kg) was determined by dividing the 
concentrations of VOC in the drinking water (mg/L) by the conversion estimate for the 
specific life stage (8 during pregnancy or 5 during lactation). For example, an 80mg/L water 
concentration would result in a 10mg/kg average daily dose for the dam each day of 
pregnancy and 16mg/kg average daily dose each day of lactation. These estimates may over 
or under shoot actual average daily doses as water consumption changes over time, but these 
calculations allow for a percent dose per gram tissue to be calculated. The conversation 
estimates were based on studies performed at the NTP on HSD pregnant and lactating rats 
(personal communication Michael DeVito, 11/24/2014). Average daily doses could only be 
estimated for the dams because conversion estimates exist for the dam during both pregnancy 
and lactation and do not exist for pups due to their rapid and variable growth rate depending 
on litter size and sex ratios of the litter. The estimated average daily dose was then multiplied 
by the weight of the dam, which was measured in this study, resulting in the amount of VOC 
ingested daily (mg). Then the percent daily dose per ml of blood was estimated by dividing 
the amount of VOCs measured in the blood divided by the estimated daily dose. For percent 
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dose, the amount measured in the blood was divided by the cumulative amounts of the VOCs 
ingested over time. Transforming the amount of each VOC in the blood to a percent of daily 
dose allows for the estimated comparison of dose between the VOCs in a mixture. 
Statistical Analysis 
For qPCR analysis, data was analyzed in Microsoft Excel and statistical significance 
was determined with Student’s t-tests. Significance was reported for p-values ≤ 0.05.  
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Results 
Half-life determination 
 There were three goals of the first study: 1) To determine if VOC levels in blood 
collected under hermetic conditions and tissues of interest could be measured, 2) to define 
any potential changes in half-life of the VOCs when given as a mixture to a pregnant rat, and 
3) determine if VOCs were being transferred to the developing fetus following oral intake 
from the dam. To accomplish these goals, whole blood, mammary gland and a fetus was 
analyzed for changes in VOC concentration over a 24 hour period. Table 3.2 reports the half-
lives of each chemical in blood, mammary gland and fetus. VC is not included since the only 
established protocol for VC detection at the CDC is in urine. Urine was not collected because 
the methods of euthanasia of the dams resulted in complete emptying of the bladder before it 
could be collected under hermetic conditions. Half-lives of the four VOCs in the blood of 
timed-pregnant rats mirrored those previously reported [1-4] following single chemical 
exposure in adult non-pregnant rats; the chemicals are eliminated quickly after gavage dose. 
The VOC with the longest half-life in the blood of a pregnant dam was PERC (about 5 ½ hr), 
followed by approximately 2 hr half-lives for the other chemicals. The data suggests that the 
half-lives of these chemicals are longer in the mammary gland of the dam and the fetus 
compared to the blood of the dam. Most of the Kow for these chemicals suggest they are 
slightly lipophilic (Tables 1.1 through 1.5) and are expected to reside longer in the mammary 
fat pad, potentially exposing mammary gland epithelium during critical periods of 
development in both the dam and the fetus and may be transferred to the milk. Importantly, 
VOCs can cross the placenta and are detected in the fetus, where it is estimated to have a 
longer half-life than in the blood of the dam.  
 
 
 
85 
 
 
Drinking water body burden 
 The VOCs were shown to have a short half-life in the gavage study and the next 
question was, “Would lower dose drinking water exposure result in a constant level of 
chemical exposure or would the dosing be more of an episodic exposure?” Dams and their 
resulting offspring were given drinking water that was either untreated or treated at 5X, 10X 
or 50X VOCs from GD 12-PND 48. Dam VOC exposure would have primarily come from 
drinking water exposure, but also potentially from ingesting urine and feces when grooming 
the young pups. Pups were exposed to VOC though gestational and lactation exposure and 
also by drinking water exposure when their eyes were open and they were big enough to 
reach the water bottle. A mixture of lactational and drinking water exposure occurred until 
they were weaned from the dams on PND 21 and then their only exposure was from drinking 
treated water. 
 The body burden data of the dam and pup is shown in Fig. 3.1 and 3.2, respectively. 
The figures suggest an episodic exposure to the VOCs; there is no accumulation over time 
with repeated doses per day. Spikes in blood concentration coincided with increased levels of 
water consumption due to lifestage (i.e., peak lactation highest; day of partition lowest). 
Large variability within some time points suggest one animal drank more recently that the 
others. PERC was given at the highest concentration and had the longest half-life of the 
chemicals tested. Therefore, it was present at the highest concentration at most time points. 
TCE and DCE remained at levels similar to background found in untreated dams. 
Surprisingly, benzene concentrations were higher than background and in the case of 10X 
pups were at higher or around the same concentration as PERC. The concentrations of 
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benzene and TCE in the drinking water were the same, while the concentration of trans-1,2-
DCE was two times higher than benzene and TCE. There was also an initial higher than 
expected amount of benzene in the blood at PND 15 for both the 10X and 50X dosed animals 
that decreased with age. A shift in VOC metabolism over time or a novel mechanism for 
benzene metabolism may be responsible for the high levels of benzene in the blood compared 
to the rest of the VOCs. 
Changes in percent dose per gram body weight and percent daily dose per gram body 
weight. 
Percent dose and percent daily dose were calculated so that comparisons of VOC 
found in the blood could be made. By comparing the percent dose found in the blood, it 
removes the differences in water concentrations of each chemical. The percent of PERC in 
the blood can be compared to the percent of TCE, without having to consider the higher 
concentration of PERC in the drinking water. Percent dose levels in the Table 3.3 shows the 
percent dose of each chemical in the 10X dam when the VOC were consumed as a mixture in 
water. Percent dose was calculated based on the percent of the VOCs detected in 1 ml of 
blood, compared to the sum of all estimated daily doses. The percent dose in blood was less 
than 1% for all chemicals after one day of exposure. PERC and benzene had similar percent 
dose over time. TCE and trans-1,2-DCE had  low percent dose values through the entire 
study. Because of the similar half-lives, benzene was expected to be comparable to DCE and 
TCE. PERC has a longer half-life and would be expected to have a higher percent dose than 
the other chemicals. With time, the percent dose typically decreased and by lactation had 
decreased to less than 0.001% for all chemicals, suggesting that these levels of VOC do not 
accumulate in the blood over time.  
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The percent daily doses in the 10X dam are listed in Table 3.4. Percent daily dose 
does not take in to account the total accumulation of VOCs from the start of exposure, but 
only the percent of the average daily dose of that timepoint found in the blood. After one day, 
PERC had the highest percent daily dose (0.066%), followed by benzene with a slightly 
lower percent daily dose (0.05%). TCE and trans-1,2-DCE percent daily doses were barely 
detectable (0.001%). After three days of exposure, the percent daily dose increased for all 
VOCs and then dropped back down at GD 21 (parturition), likely due to the dramatic 
changes in water intake. During lactation, the percent daily dose increased to the highest 
levels for all VOCs on PND 15, the peak of lactation, and then were back down to levels 
similar to the first day of dosing by weaning. Again, these changes were in line with expected 
water intake levels.  
CYP mRNA expression in liver from water exposure studies. 
Decreasing benzene concentrations over time were noted in the blood of offspring 
exposed to 10X and 50X concentrations of VOC. A possible explaination could be that 
VOCs are increasing the expression of CYP enzymes with increasing age and metabolizing 
the benzene at a faster rate. To determine whether VOC exposure induced changes in CYP 
expression pathways responsible for VOC metabolism (Cyp2e1 and Cyp2b1), livers were 
evaluated from male pups on PND 15, 21, 28 and 48. Fold change gene expression for 
Cyp2e1 and Cyp2b1 are shown in Table 3.5 and 3.6. There were few dose and/or dose/time-
dependent gene changes found in the tissues evaluated. VOC exposure significantly down-
regulated expression of Cyp2e1 at PND 48, at the 10X concentration. The same effect was 
seen in Cyp2b1 expression; there was a significantly down-regulated expression of Cyp2b1 
at PND 48 at the 10X concentration. When looking at CYP expression over time, in Tables 
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3.7 and 3.8, there was a significant down-regulation in Cyp2e1 at PND 48 in control, 10X 
and 50X dose group compared to PND 15. There was a significant down-regulation in 
Cyp2b1 expression at PND 48, when compared to PND 15, at the 10X concentration. This 
shift in expression over time suggests that Cyp2e1 has higher expression during 
neonatal/prepubertal time points. Similar effects in Cyp2e1 activity changes have been 
observed other strains of rat [24]. 
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Discussion   
A gavage dose of the VOC mixture allowed for a validation in the collection and 
detection protocols, a half-live determination in tissues of interest, and confirmation that 
VOCs were transferred to mammary tissue (and potentially milk) and the developing fetus. 
These were important premises to establish for the rest of the studies I propose. The blood 
half-lives of the VOCs were comparable to the half-lives previous determined in non-
pregnant rats [1-5]. Benzene, at high concentrations has an initial rapid excretion phase (41 
mins) followed by a slower elimination rate. At low exposure concentrations (6.4 ppm), a 
less rapid elimination rate is seen (1.2 hours) [1] and this closely matches the findings in the 
pregnant dam in these studies of a half-life of 1.6 hours. In rats, PERC has been shown to 
have a half-live of 5.3 hours in the blood and 9.6 hours in the fat [2]. The half-life of PERC 
in the blood of pregnant rats (5.7 hr) matched closely to previous findings in non-pregnant 
rats and in the mammary gland, PERC had a longer half-life (6.8 hr), closer to the previous 
reported half-life in fat of 9.6 hours. The half-life of PERC reported in humans can be much 
longer than in the rat, especially in the fat; up to 55 hours [2]. TCE has been reported to have 
a short half-life in non-fasted rats of around 3 hours verses 2 hours in fasted rats [3]. The 
pregnant dams in this study were not fasted but had a half-life similar to previously studied 
fasted male rats (2 hr) [25]. trans-1,2-DCE has not been as extensively studied as the other 
three chemicals, cis-1,2-DCE has an estimated half-life of less than one hour in the blood of 
humans [12]. The present study demonstrated that in the pregnant rat the half-life of DCE in 
the blood is just over an hour and a half and is closer to two hours in the mammary gland. 
VC could not be detected in the blood and urine analysis would be necessary to make half-
life estimations. Because of the nature of the euthanasia of the animals (CO2 knockdown and 
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then terminal cardiac puncture) the bladders were emptied by the time of necropsy and urine 
could not be collected without exposure to the air and potential loss of VOCs due to 
volatilization.  
VOCs were detected in both the mammary gland and fetus, thus it is reasonable to 
assume that the offspring were exposed to VOC both transplacentally and from ingesting 
contaminated milk from the dam, in addition to ingestion of VOC-laced drinking water once 
they could reach the water. The half-lives of VOCs in the fetus compared to the blood or 
mammary gland varied with each chemical. The fetal half-lives were slightly longer than in 
the dam with the exception of PERC, where the high-life was approximately the same. The 
half-lives of the chemicals found in the blood of the pregnant rat did not vary from what have 
previously seen in the adult non-pregnant rat and as anticipated, these chemicals have a 
longer half-life in fatty tissue; the mammary gland. These VOC are mildly lipophilic, as 
evidenced by Kow in Chapter 1, but the mammary gland does not have a very high perfusion 
rate compared to other tissues [26]. PERC can accumulate in humans [2], and it was 
important to see if blood levels of VOC would ever reach a plateau or steady state. 
Considering the episodic nature of the exposure from drinking water, the low concentrations 
given, and the short chemical half-lives, VOC concentrations in the rat were not expected to 
and did not reach a steady state exposure. The concentrations found in the blood were likely 
dependent on the amount of water consumed and how recently before necropsy they last 
drank, neither of which was exactly known. 
 Blood concentrations of PERC were expected to be the highest among the chemicals 
measured in all treated groups, as PERC was at the highest concentration in the VOC mixture 
(Table 3.1). Blood concentrations of PERC in the dams were the highest concentration of any 
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of the other compounds. Blood concentrations of benzene, TCE and trans-1,2-DCE were 
close to background levels for the majority of animals (with the exception of 50X treated 
dams and 10X treated dams at PND 21). Blood concentrations of benzene were the second 
highest in all the treated groups and were up to 10 times higher than TCE or trans-1,2-DCE. 
This was surprising since the half-lives and the concentrations of benzene and TCE in the 
drinking water are approximately equal. Even more so that the half-lives of benzene and 
trans-1,2-DCE  are also equal yet there is twice the concentration of trans-1,2-DCE  in the 
drinking water than benzene. Benzene had an even more elevated presence in the pups. In the 
50X dosed offspring, PERC was in general much higher than the other chemicals, with the 
exception of benzene. At PND 15, benzene levels were elevated to concentrations similar to 
PERC. PERC blood levels generally increased with age, while benzene levels decreased with 
age. In the 10X exposed offspring, blood benzene levels were higher than PERC until PND 
48, despite being found at 1/15
th
 the amount in the water. Like the 50X treated animals, 
benzene blood levels decreased with age. TCE and trans-1,2-DCE also remained at 
background levels in the offspring, with only one slight peak in trans-1,2-DCE levels in the 
50X offspring at PND 21. The benzene trends were unexpected.  
 Since the concentrations of each VOC in the drinking water varied, an estimated 
percent dose and percent daily dose calculations in the dam were made to be able to compare 
the VOC exposures. Actual percent dose and percent daily doses cannot be determined 
because the drinking water consumption of each rat is unknown. Water consumption was not 
recorded because, once the pups could start drinking water and after weaning when the 
offspring were group housed, it would be unknown how much water each individual 
consumed. The NTP has performed many studies testing chemical exposure both through 
 
 
92 
 
drinking water and diet. Exact water and food consumption in studies where animals are 
group housed (reproductive assessment by continuous breeding, 2-Year bioassay and 13-
week exposure studies) cannot be determined and so conversion estimates were developed to 
roughly estimate average daily dose in the HSD rats. The conversion estimates where 
determined by comparing the concentration in the water or diet and amounts of chemical 
actually in the animal. The conversion estimates allow for an estimation of average daily 
dose from drinking water or diet exposures when designing a dose-range finding study. The 
conversation estimates make some assumptions, namely that the conversion estimate is 8 
between GD 9-21 and 5 during lactation and that the concentration of a chemical in the water 
or diet will not change over time. By changing the water frequently, variability in VOC 
concentrations was minimized. Despite being potentially inaccurate, the estimated percent 
dose and daily dose allowed for the comparisons between the VOCs and revealed both 
anticipated and unanticipated results. Comparing the VOC half-lives to their percent doses 
and percent daily dose, benzene, TCE and trans-1,2-DCE were expected to have similar 
percent doses and percent daily doses, but benzene was 10-50 times higher during pregnancy. 
Some property of benzene or the VOCs as a mixture makes the percent dose and percent 
daily dose of  benzene in the blood higher than TCE or trans-1,2-DCE, despite similar half-
lives, amount in the dosing solution and Kow.  
The major enzyme for metabolizing benzene, PERC, TCE, trans-1,2-DCE and VC in 
the liver is Cyp2e1 [1-5]. Elimination of benzene may be affected by the mixture of VOCs 
that makes the percent dose so much higher than TCE or trans-1,2-DCE. PERC has the 
longest half-life of all the chemicals and was expected to have the highest percent dose at all 
time points.  
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 Major metabolism of these chemicals in the liver are dependent on Cyp2e1 (Benzene, 
PERC, TCE, trans-1,2-DCE and VC) and Cyp2b1 (PERC). The ontogeny of CYP liver 
enzyme expression (measured either by mRNA expression, protein levels and/or activity) in 
rats from gestation through adulthood has previously been summarized [24]. For both 
Cyp2e1 and Cyp2b1 there is very low hepatic expression and/or activity during gestation. 
Fetuses depend on maternal metabolizing enzymes until birth. Cyp2b1 expression in the liver 
of the pups is higher than adult levels from parturition until weaning. Cyp2e1 expression 
remains low the first few days after birth and becomes higher than adult levels until weaning 
[24]. In this study, the control offspring were expected to start with high expression at PND 
15 and then CYP levels would decrease by later time points to the normal adult expression 
levels. Because of the limited amount of liver samples collected only mRNA was collected 
and analyzed by qPCR for CYP expression. When comparing CYP expression over time, we 
detected the expected significant down regulation of Cyp2e1 in the Control, 10X and 50X 
dosed animals at PND 48, compared to PND 15. The same significant down regulation of 
Cyp2b1 expression was found in the 10X dosed animals, but there was no difference in the 
control, 5X or 50X dosed animals over time. VOC exposure did not significantly change 
CYP expression for the majority of treated animals, and changes in CYP expression cannont 
explain the unexpectedly high levels of benzene in pup blood.  
Although activity was not directly measured, it seems unlikely that low levels of 
VOCs given in this study would alter the activity of CYPs to a significant level. There is a 
possibility that the blood benzene levels drop due to dilution in the quickly growing pup, but 
a similar drop in PERC would have also been expected. Some of the limitations of these 
studies come from the desire to closely recapitulate water exposure at Camp Lejeune. Future 
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studies would benefit from recording water consumption for the dams before the pups can 
reach the water bottles. Future studies should also examine the effects of the mixture of 
VOCs on the activity of the CYP enzymes. Rats exposed to 40 ppm trans-1,2-DCE before 
VC or TCE exposure were reported to have reduced metabolism due to trans-1,2-DCE 
competitive inhibition of Cyp2e1 [27]. The low levels of the VOCs in mixture do not induce 
a change in mRNA expression but may compete for Cyp2e1, altering metabolism of the 
mixture. 
In the previous chapter, it was important to determine how the mammary gland 
development of the HSD rat was affected under normal and chemically altered conditions. In 
this chapter, these studies determined how each VOC behaves: 1) in a gestational/lactational 
drinking water exposure, where body weights change daily and 2) as a mixture with other 
similarly metabolized and excreted VOCs. The toxicokinetics of these individual chemicals 
have mostly been studies in adult animals, where body weights and compartment sizes don’t 
fluctuate significantly.  These studies are focused on human relevant exposures to VOCs 
when consuming contaminated drinking water. It was important to understand and 
recapitulate the VOC exposure in pregnant mothers and children/young adult at sites like 
Camp Lejeune. With a general understanding of the mammary gland development and VOC 
body burden in HSD rat, Chapter 4 will assess VOC exposure on the mammary gland. 
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Table 3.1 VOC concentrations in well water at Camp Lejeune, in drinking water studies, and 
in the 100X gavage dose used in the half-life study 
  PERC TCE trans-1,2 DCE VC Benzene 
1X ppm in well water [20] 1.5 0.2 0.4 0.025 0.2 
5X μg/ml in water 7.5 1 2 0.125 1 
10X μg/ml in water 15 2 4 0.25 2 
50X μg/ml in water 75 10 20 1.25 10 
Half-life study mg/kg in sesame oil 150 20 40 2.5 20 
Note: VOC= volatile organic compound. HSD= Harlan Sprague Dawley. GD= gestational day. 
PERC= tetrachloroethylene. TCE= trichloroethylene. trans-1,2-DCE= trans-1,2-dichloroethylene. 
ppm  is equivalent to μg/ml. 
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Table 3.2 Calculated VOC half-lives (in hours) in pregnant HSD rat and fetus at GD 15 
Dam Benzene  PERC  TCE  trans-1,2 DCE  
Blood 1.61 5.62 1.99 1.52 
Mammary Gland 2.12 6.77 2.22 1.98 
Fetus     
Fetus 2.34 5.61 2.12 2.03 
Note: VOC= volatile organic compound. HSD= Harlan Sprague Dawley. GD= gestational day. 
PERC= tetrachloroethylene. TCE= trichloroethylene. trans-1,2-DCE= trans-1,2-dichloroethylene.  
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Table 3.3 Percent dose per 1 ml blood in the 10X HSD dam 
  Benzene  PERC TCE trans-1,2 DCE 
GD 13 0.050% 0.066% 0.001% 0.001% 
GD 15 0.016% 0.022% <0.001% <0.001% 
GD 21 0.007% 0.026% 0.001% <0.001% 
PND 15 <0.001% <0.001% <0.001% <0.001% 
PND 21 <0.001% <0.001% <0.001% <0.001% 
Note: HSD= Harlan Sprague Dawley. PERC= tetrachloroethylene. TCE= trichloroethylene. trans-
1,2-DCE= trans-1,2-dichloroethylene. GD= gestational day. PND= postnatal day.  Calculated as: the 
amount of VOC measured in 1 ml of blood divided by the sum of the estimated average daily mg 
dose with exposures starting on GD 12. The average daily dose was estimated by dividing the 
concentration of VOCs in the drinking water by a conversion estimate (8 for GD 12-21 and 5 for 
PND 1-21) and multiplying by the average body weight of the dam on the day of blood collection. 
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Table 3.4 Percent daily dose per 1 ml blood in the 10X HSD dam 
 Benzene PERC TCE trans-1,2 DCE 
GD 13 0.050% 0.066% 0.001% 0.001% 
GD 15 0.057% 0.226% 0.005% 0.004% 
GD 21 0.041% 0.090% 0.002% 0.002% 
PND 15 0.105% 0.179% 0.106% 0.043% 
PND 21 0.027% 0.110% 0.001% 0.004% 
Note: HSD= Harlan Sprague Dawley. PERC= tetrachloroethylene. TCE= trichloroethylene. trans-
1,2-DCE= trans-1,2-dichloroethylene. GD= gestational day. PND= postnatal day.  Calculated as: the 
amount of VOC measured in 1 ml of blood divided by the estimated average daily mg dose. The 
average daily dose was estimated by dividing the concentration of VOCs in the drinking water by a 
conversion estimate (8 for GD 12-21 and 5 for PND 1-21) and multiplying by the average body 
weight of the dam on the day of blood collection. 
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Table 3.5 Fold change of Cyp2e1 mRNA expression in VOC treated offspring 
 PND 15 PND 21 PND 28 PND 48 
5X -1.62 -1.43 1.01 1.80* 
10X 1.26 -1.14 1.04 -1.01 
50X 1.25 -1.55 -1.37 1.28 
Note: VOC= volatile organic compound. PERC= tetrachloroethylene. TCE= trichloroethylene. trans-
1,2-DCE= trans-1,2-dichloroethylene. PND= postnatal day. Significant effects compared to controls 
by Student’s t-test,*p≤0.05. mRNA expression in control rat is 1. 
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Table 3.6 Fold change of Cyp2b1 mRNA expression in VOC treated offspring 
 PND 15 PND 21 PND 28 PND 48 
5X -1.13 1.14 -1.49 -1.68 
10X 1.25 1.12 -1.44 -2.20* 
50X -1.13 -1.16 1.07 1.41 
Note: VOC= volatile organic compound. PERC= tetrachloroethylene. TCE= trichloroethylene.            
trans-1,2-DCE= trans-1,2-dichloroethylene. PND= postnatal day. Significant effects compared to 
controls by Student’s t-test,*p≤0.05. mRNA expression in control rat is 1. 
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Table 3.7 Fold change of Cyp2e1 mRNA expression over time in VOC treated offspring 
 Control 5X 10X 50X 
PND 21 1.37 1.55 -1.05 -1.04 
PND 28 1.25 2.04 1.03 -1.37 
PND 48 -2.05* 1.43 -2.61* -2.00* 
Note:. VOC= volatile organic compound. PERC= tetrachloroethylene. TCE= trichloroethylene. trans-
1,2-DCE= trans-1,2-dichloroethylene. PND=postnatal day. Significant effects compared to PND 15 
by Student’s t-test,*p≤0.05. mRNA expression in PND 15 rat is 1. 
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Table 3.8 Fold change of Cyp2b1 mRNA expression over time in VOC treated offspring 
 Control 5X 10X 50X 
PND 21 -1.35 -1.05 -1.50 1.46 
PND 28 -1.10 -1.45 -1.96 1.72 
PND 48 1.07 1.70 -2.55* 1.12 
Note: VOC= volatile organic compound. PERC= tetrachloroethylene. TCE= trichloroethylene.          
trans-1,2-DCE= trans-1,2-dichloroethylene. PND=postnatal day.  Significant effects compared to 
PND 15 by Student’s t-test,*p≤0.05. mRNA expression in PND 15 rat is 1. 
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Figure 3.1 VOC blood concentrations (ng/ml) in dams exposed to VOC mixture in 
drinking water. (A) Control dam. (B) 5X dam. (C) 10X dam. (D) 10X dam with PERC 
removed. (E) 50X dam. (F) 50X dam with PERC removed. The detection limits achieved 
with this method were 5, 24, 5, and 8 pg/ml for 1,2-DCE, benzene, TCE, and PERC,  
respectively 
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Figure 3.2 VOC blood concentrations (ng/ml) in offspring exposed to VOC mixture in 
drinking water. (A) 10X offspring. (B) 50X offspring. The detection limits achieved with 
this method were 5, 24, 5, and 8 pg/ml for trans-1,2-DCE, benzene, TCE, and PERC,  
respectively 
 
 
 
  
 
 
105 
 
REFERENCES 
1. ATSDR, Toxicological Profile for Benzene, U.S. Department of Health and Human 
Services, Editor. 2007, Agency for Toxic Substances and Disease Registry. 
 
2. ATSDR, Draft Toxicological Profile for Tetrachloroethylene, U.S. Department of 
Health and Human Services, Editor. 2014, Agency for Toxic Substances and Disease 
Registry. 
 
3. ATSDR, Draft Toxicological Profile for Trichloroethylene, U.S. Department of 
Health and Human Services, Editor. 2014, Agency for Toxic Substances and Disease 
Registry. 
 
4. ATSDR, Draft Toxicological Profile for Vinyl chloride, U.S. Department of Health 
and Human Services, Editor. 2006. 
 
5. ATSDR, Toxicological Profile for 1,2-Dichloroethene, U.S. Department of Health 
and Human Services, Editor. 1996, Agency for Toxic Substances and Disease 
Registry. 
 
6. Common Chemicals Found at Superfund Sites. 2011; Available from: 
http://www.epa.gov/superfund/health/contaminants/radiation/chemicals.htm. 
 
7. Bove, F. J., P. Z. Ruckart, M. Maslia, and T. C. Larson. 2014. Mortality study of 
civilian employees exposed to contaminated drinking water at USMC Base Camp 
Lejeune: a retrospective cohort study. Environ Health 13:68. 
 
8. EPA, U.S., Toxicological Review of Trichloroethylene (CAS No. 79-01-6). 2011, U.S. 
Environmental Protection Agency: Washington, DC  
 
9. EPA, U.S., Carcinogenic effects of benzene: An update. , Prepared by Office of 
Research and Development, Editor. 1998: Washington, DC. 
 
10. EPA, U.S., Toxicological Review oF Tetrachloroethylene (Perchloroethylene) (CAS 
No. 127-18-4). 2012, U.S. Environmental Protection Agency: Washington, DC  
 
11. EPA, U.S., Toxicological Review of Vinyl chloride (CAS No. 75-01-4). 2000, U.S. 
Environmental Protection Agency: Washington, DC  
 
12. EPA, U.S., Toxicological Review of cis-1,2-Dichloroethylene and trans-1,2-
Dichloroethylene (CAS Nos. cis: 156-59-2; trans: 156-60-5; mixture: 540-59-0). 
2010, U.S. Environmental Protection Agency: Washington, DC  
 
13. Anderson, J. R. 2012. Alarming breast cancer rates among troops reported. USA 
TODAY.com. 
 
 
 
106 
 
13. Sabourin, P. J., W. E. Bechtold, W. C. Griffith, L. S. Birnbaum, G. Lucier and R. F. 
Henderson, Effect of exposure concentration, exposure rate, and route of 
administration on metabolism of benzene by F344 rats and B6C3F1 mice. Toxicol 
Appl Pharmacol, 1989. 99(3): p. 421-44. 
 
14. Kim, D. and B.I. Ghanayem, Comparative metabolism and disposition of 
trichloroethylene in Cyp2e1-/-and wild-type mice. Drug Metab Dispos, 2006. 34(12): 
p. 2020-7. 
 
15. Bull, R.J., Mode of action of liver tumor induction by trichloroethylene and its 
metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect, 2000. 
108 Suppl 2: p. 241-59. 
 
16. Lin, E. L., J. K. Mattox, and F. B. Daniel. 1993. Tissue distribution, excretion, and 
urinary metabolites of dichloroacetic acid in the male Fischer 344 rat. J Toxicol 
Environ Health 38:19-32. 
 
17. Jenkins, L.J., Jr., M.J. Trabulus, and S.D. Murphy, Biochemical effects of 1,1-
dichloroethylene in rats: comparison with carbon tetrachloride and 1,2-
dichloroethylene. Toxicol Appl Pharmacol, 1972. 23(3): p. 501-10. 
 
18. Lash, L. H., D. A. Putt, P. Huang, S. E. Hueni and J. C. Parker, Modulation of hepatic 
and renal metabolism and toxicity of trichloroethylene and perchloroethylene by 
alterations in status of cytochrome P450 and glutathione. Toxicology, 2007. 235(1-
2): p. 11-26. 
 
19. Chiu, W.A. and G.L. Ginsberg, Development and evaluation of a harmonized 
physiologically based pharmacokinetic (PBPK) model for perchloroethylene 
toxicokinetics in mice, rats, and humans. Toxicol Appl Pharmacol, 2011. 253(3): p. 
203-34. 
 
20. Sonnenfeld, N., I. Hertz-Picciotto, and W.E. Kaye, Tetrachloroethylene in drinking 
water and birth outcomes at the US Marine Corps Base at Camp Lejeune, North 
Carolina. Am J Epidemiol, 2001. 154(10): p. 902-8. 
 
21. Blount, B. C., R. J. Kobelski, D. O. McElprang, D. L. Ashley, J. C. Morrow, D. M. 
Chambers and F. L. Cardinali, Quantification of 31 volatile organic compounds in 
whole blood using solid-phase microextraction and gas chromatography-mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2006. 832(2): p. 292-
301. 
 
22. Chambers, D. M., B. C. Blount, D. O. McElprang, M. G. Waterhouse and J. C. 
Morrow, Picogram measurement of volatile n-alkanes (n-hexane through n-
dodecane) in blood using solid-phase microextraction to assess nonoccupational 
petroleum-based fuel exposure. Anal Chem, 2008. 80(12): p. 4666-74. 
 
 
 
107 
 
23. Troester, M. A., A. B. Lindstrom, L. L. Kupper, S. Waidyanatha, and S. M. 
Rappaport. 2000. Stability of hemoglobin and albumin adducts of benzene oxide and 
1,4-benzoquinone after administration of benzene to F344 rats. Toxicol Sci 54:88-94. 
 
24. Saghir, S.A., S.A. Khan, and A.T. McCoy, Ontogeny of mammalian metabolizing 
enzymes in humans and animals used in toxicological studies. Crit Rev Toxicol, 
2012. 42(5): p. 323-57. 
 
25. EPA, U.S., Sources, emission and exposure for trichloroethylene (TCE) and related 
chemicals 2001, U.S. Environmental Protection Agency Washington, DC  
26. Johnson, R. L., M. Gilbert, G. Meschia, and F. C. Battaglia. 1985. Cardiac output 
distribution and uteroplacental blood flow in the pregnant rabbit: a comparative 
study. Am J Obstet Gynecol 151:682-686. 
 
27. Barton, H. A., J. R. Creech, C. S. Godin, G. M. Randall and C. S. Seckel, 
Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl 
chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol Appl 
Pharmacol, 1995. 130(2): p. 237-47. 
 
 
 
 
108 
 
CHAPTER 4: Mammary developmental effects and tumor susceptibility in Harlan 
Sprague Dawley rats following in utero and adolescent exposures to a VOC mixture in 
drinking water 
INTRODUCTION 
 Volatile organic compounds (VOCs) are a subset of organic compounds with physical 
and chemical properties that allow them to move between water and air. VOCs tend to have 
high vapor pressures, low-to-medium water solubility, and low molecular weights. Some 
VOCs occur naturally in the environment, while others are manmade or both [1]. VOCs are 
detected in many aquifers across the U.S. and their presence in drinking water may pose a 
risk to human health because of their potential carcinogenicity. VOCs are quickly eliminated 
from the body (half-life 1-9 hours[2-6]). VOCs can be exhaled unchanged, but a portion can 
be bioactivated to form reactive metabolites. From human and animal studies, certain VOCs 
have been associated with a wide range of cancers including liver, kidney, immune, 
neurological, and reproductive, as well as developmental toxicity. There is limited human 
data supporting associations between VOC exposures and breast cancer [2-11], but animal 
evidence has been reported. 
Breast cancer in women is the most commonly diagnosed form of cancer and the 
second highest killer of women, after lung cancer [12]. In contrast, male breast cancer is 
exceedingly rare yet incidence rates in male breast cancer are rising [12]. A “hot spot” of 
male breast cancer is developing around the Marine Corp Base, Camp Lejeune. Over 80 men 
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who developed breast cancer in the last 10 years with residential ties to Camp Lejeune 
believe VOC exposure through contaminated well water was an important risk factor in their 
breast cancer development [13]. Male breast cancer is understudied in animal models. The 
male rat and mouse mammary gland have been demonstrated to be sensitive to EDCs [14, 
15], and further testing of VOCs during windows of susceptibility in the mammary gland are 
needed to reveal if there is a potential link between male breast cancer and VOC exposure. 
As described in Chapter 1, the mammary gland functions to provide nutritional 
sustenance to offspring and the organ continues to develop throughout life. The mammary 
gland undergoes its first period of rapid growth during embryogenesis. It continues to further 
develop after birth; during puberty and pregnancy. Normal mammary gland development 
involves the communication between mammary stromal cells and epithelium to direct normal 
mammary ductal tree elongation and branching. Following lactation and during menopause, 
involution occurs and the mammary gland is remodeled through apoptosis.  
During the pubertal expansion of the mammary gland, terminal end buds (TEBs) 
proliferate as ductal elongation and branching occurs. TEBs are the highly proliferative end 
units, where most of the growth of the mammary epithelium takes place and are consequently 
highly susceptible to carcinogenic insults [16]. Once the mammary gland has reached the 
edge of the fat pad or encounters other glands, the TEBs differentiate and mature into 
terminal ends. TEBs are abundant during puberty and differentiate as the mammary gland 
matures. TEBs are particularly sensitive to carcinogens and when they are present in the 
gland, this represents a window of susceptibility for the mammary gland. Chemically-
induced mammary tumorigenesis with the mammary-specific carcinogen, 7, 12-
dimethylbenz[a]anthracene (DMBA) occurs primarily in the epithelium of TEB and the 
 
 
110 
 
administration of DMBA to rodents during puberty induces the largest number of 
transformed TEBs, resulting in an increased tumor burden[16-18].  
The Harlan Sprague Dawley (HSD) mammary gland atlas in Chapter 2 characterized 
male and female tissue development and gave examples of the early morphological changes 
following prenatal EDC exposure that may occur. Studies testing EDCs, like Bisphenol A, 
have found altered mammary gland maturation rates, enhanced ductal growth and increased 
susceptibility to carcinogenesis following DMBA-administration [17, 19-23]. Further, in 
Chapter 3, I determined that there is transplacental and potentially lactational exposure to 
pups following a Camp Lejeune relevant drinking water exposure to VOCs in the HSD rat. 
The present studies were designed to evaluate the effects of five VOCs, as a mixture, on 
mammary gland development and tumor susceptibility in male and female rats following 
gestation early life exposure.  Of the five VOCs tested in this study, PERC and TCE are 
potentially EDCs. PERC exposure has been associated with menstrual disorders and TCE 
may reduce FSH and testosterone levels in men [24, 25]. Furthermore, benzene and vinyl 
chloride have been shown to cause mammary tumor development in female rodents when 
delivered at high doses over their adult life [2,5].  In this study, timed-pregnant HSD rats 
were exposed to the same mixture of chemicals as in Chapter 3; 0, 5X and 10X, in the 
drinking water from GD 12-PND 48. 1X concentrations of VOCs is the level measured in the 
well water at Camp Lejeune[26]. Mammary glands were collected at PND 23 and 48 and 
evaluated for growth patterns. A subset of offspring were dosed with DMBA on PND 30 to 
initiate mammary gland carcinogenesis and assess the ability of VOCs to sensitize mammary 
glands to a carcinogen. 
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Materials and Methods 
Animals 
Time pregnant HSD rats, obtained from Harlan Laboratories (Indianapolis, IN), 
arrived on GD 10 (GD 0 is defined as plug positive) and allowed to acclimate for 2 days. 
Pregnant dams were housed individually in polypropylene cages with bedding and nestlets 
and switched to a rodent phytoestrogen-reduced diet on arrival (Zeigler; Madison, WI) and 
received chow ad libitum. Animal facilities were maintained on a 12:12 h light-dark cycle at 
20°C–23°C and 40–50% relative humidity. All animal studies were approved by the NIEHS 
Animal Care and Use Committee. 
Chemicals 
VOC drinking water solutions were prepared as in Chapter 3. Ampules (1 mL) 
containing standard mixture of benzene, PERC, TCE and t-1,2-DCE were purchased by the 
Centers for Disease Control and Prevention (CDC) from O2si (Charleston, SC) and VC 
(2000µg/ml) was purchased from Sigma Aldrich (Steinhiem, Switzerland). VOC drinking 
water solutions were prepared by spiking 38.85 µl of the standard and 312.5 µl of VC into 
500 ml reverse osmosis/deionized water resulting in 10 µg/ml of benzene, 75 µg/ml of 
PERC, 10 µg/ml of TCE, 20 µg/ml of t-1,2-DCE and 1.25 µg/ml of VC for the “50X” 
concentration. Serial dilutions were made for “10X” and “5X” concentrations (Table 3.1). 
500 ml glass drinking water bottles with metal sippers, filled with dosed drinking water, were 
given to animals to drink ad libitum. Pilot experiments showed that VOC off-gassing 
depends more on the amount of head space in the water bottle than the length of time since 
freshly mixed. The drinking water bottles were changed at least every other day to ensure no 
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more than 25% of the water was consumed, to reduce the changes in VOC water 
concentrations. 
Experimental Design 
Two studies were conducted to determine the effects of a mixture of VOC on body 
burden. 
Early mammary gland effects study: Time-pregnant HSD rats (60 dams) arrived at 
NIEHS on gestation day (GD) 10 and were divided into 3 treatment groups, control (n=15), 
5X (n=15) and 10X (n=30) of equal average body weight. Seven dams were not pregnant and 
were removed from the study (two from control, one from 5X and four from 10X). Each dam 
and subsequent pups were given treated water to drink ad libitum until sacrifice. At PND 4 
pups were culled and litters were equalized to five male and five female pups. 
Carcinogen-induced mammary cancer study: A subset of male and female pups 
(n=52-56  per treatment) from each group of the early mammary gland effects study were 
reserved for DMBA dosing. An additional 52 10X VOC offspring were not given DMBA, 
but were otherwise treated similar to DMBA treated animals.  DMBA (30 mg/kg body 
weight) was given at PND 30 to all remaining dose groups (Control+DMBA, 5X+DMBA 
and 10x+DMBA) via oral gavage in sesame oil (5 mL/kg body weight). Pups continued to 
drink treated water until PND 48 and then were switched to tap water. Pups underwent 
weekly mammary gland palpations and tumor latency and size were recorded by gland, size 
and date. Animals were sacrificed about 30 weeks after birth and 26 weeks after DMBA 
administration. 
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Necropsy 
Early mammary gland effects study: 12 pups per sex per dose group were 
sacrificed on PND 23 and 48 by CO2 asphyxiation. Terminal cardiac puncture was performed 
and blood was collected from the left ventricle for serum and blood smear. Whole body, liver 
and spleen weights were recorded. One set of 4
th
 and 5
th
 mammary glands were removed for 
whole mount analysis and the contralateral set was collected into histology cassettes and 
fixed in formalin for immunohistochemistry (IHC) processing. Sections of liver, spleen, 
thymus and femur were collected into histology cassettes and fixed in formalin for histology 
evaluations. A section of liver and mammary gland were flash frozen for RNA analysis. The 
pathology of the liver, spleen, bone and thymus will not be discussed here as they were part 
of another project. 
Carcinogen-induced mammary cancer study: Four offspring (two males and two 
females) per dam from each dose group (n=52, 56, 52, and 52 from control+DMBA, 
5X+DMBA, 10X+DMBA and 10X-DMBA) were sacrificed at 30 weeks after birth by CO2 
asphyxiation. Body weights were recorded and blood was collected by terminal cardiac 
puncture. All organs were examined for lesions and mammary glands were removed for 
histology, along with any other apparent masses. Mammary tumors were measured and size 
recorded. Livers were collected and weighed. A portion of liver and mammary gland were 
snap-frozen in a cryo vial for future studies. The following additional target tissues were 
collected and fixed in 10% formalin for histology: liver, spleen, lung (infused with formalin), 
thymus, right and left kidney, adrenal, submandibular lymph nodes, uterus and ovaries. 
Again, the effects of the VOCs on these tissues are not reported here as they are part of 
another project. 
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Mammary Gland Preparations 
Mammary glands whole mounts were prepared and stained with carmine alum as 
described in [27]. Images of whole mounts were evaluated on a Leica DM2000 or Z16 APO 
with a Leica DFC295 Camera (Leica Microsystems, Frankfurt, Germany). Using the 
evaluation criteria specified in Davis and Fenton (2013) [28], a qualitative developmental 
score was given. A score of 4 represented a gland that was most well developed, while a 
score of 1 represented few of the necessary criteria needed. Generally, the criteria for a HSD 
PND 23 female mammary gland to receive a 4 included: 1) growth of the 4
th
 gland past the 
lymph node, 2) 4
th
 and 5
th
 glands had grown together, 3) generous branching buds and TEBs 
on the ducts and 4) lobule formation started throughout the gland. The criteria for a HSD 
PND 48 female mammary gland to receive a 4 include: 1) few to no TEBs present, 2) growth 
to the edges of the fat pad, 3) very dense branching and 4) multi-unit lobules present. HSD 
male rats had similar criteria as the females with the exception of criteria regarding the 5
th
 
gland. Control male glands were similar to control female glands at PND 23 and were 
slightly more differentiated than female glands at PND 48. The 5
th
 gland in 50% of the males 
never formed, in both treated and control rats. Mammary gland assessments were based on 
the development of the 4
th
 gland. Scorers reviewed controls in each age/sex group prior to 
sorting the entire set of slides by score. Slides within a score were compared once segregated 
for uniformity of scoring, before reporting scored for individual slides. Scoring was 
performed by two reviewers without knowledge of treatment, and the two scores were 
averaged. Mean scores for treatment groups were calculated for each time point and analyzed 
for statistical significance. 
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ERα and PR immunohistochemistry 
Normal mammary tissue and tumor sections were deparaffinized and rehydrated 
through a series of alcohols to 1X PBS.  Endogenous peroxidase was blocked with 3% 
hydrogen peroxide.  Heat induced antigen retrieval as performed using citrate buffer pH 6.0 
(Biocare Medical, Concord, CA) at 120 °C for 5 minutes in a decloaking chamber (Biocare 
Medical).  The sections were incubated with 10% normal horse serum (Jackson 
Immunoresearch Laboratories, Inc., West Grove, PA) for 20 minutes. Endogenous biotin was 
quenched with the Avidin-Biotin Blocking Kit (Vector Laboratories, Burlingame, CA.  
Sections were incubated with either anti-estrogen receptor alpha antibody at a 1:50 dilution 
(Beckman Coulter, Brea, CA; catalog # IM1545) or anti-progesterone receptor antibody at a 
1:150 dilution (Beckman Coulter, Brea, CA; catalog # IM1546). For a negative control, 
sections were incubated with mouse IgG1 isotype control serum in place of the primary 
antibody (BD Biosciences, San Diego, CA) for 60 minutes at 1:50 dilution. Sections were 
incubated with the secondary antibody, horse anti-mouse secondary antibody (Vector 
Laboratories) for 30 minutes at 1:1000 dilution and then labeled (Vector R.T.U. Vectastain 
Kit, Vector Laboratories) for 30 minutes. Antigen-antibody complex was visualized 
following a 6 minute incubation with 3, 3' diaminobenzidine (Dako Corporation, Carpinteria, 
CA). The sections were counterstained with modified Harris hematoxylin, dehydrated, 
cleared and coverslipped with Permount. 
Statistical Analysis 
Unpaired, two-tailed, equal variance t tests, Cochran-Armitage trend test and log-rank 
(Mantel-Cox) test of survival curves were performed in GraphPad Prism 6.0. The threshold 
for statistical significance was set at p≤ 0.05. 
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Results 
Developmental VOC exposure alters body weights and relative liver weights 
Body weights were recorded on days of necropsy as an indicator of toxicity in female 
and male offspring. At PND 30, male offspring in the 10X exposure group demonstrated a 
transient 6% body weight increase over controls. At PND 48, females and males in the 10X 
exposure group were 6% and 5%, respectively, lighter than controls. The reason for this shift 
in body weight is unknown, but could be due to decreased food or water consumption in 
those dose groups. Water consumption was not recorded in this study, as a pilot study did not 
show decreased VOC-laced water consumption.  Absolute and relative (liver:body weight) 
liver weights were significantly decreased in both females and males dosed with 10X VOC at 
PND 48. Body and liver weights can be found in Table 4.1 and 4.2.  
Developmental VOC exposure leads to aberrant mammary growth  
 The focus of this study was mammary gland development and growth in VOC-
exposed rats and the potential mammary tumor risk following carcinogenic induction. 
Mammary glands of VOC-exposed females and males (late gestation through puberty) 
displayed characteristics of accelerated development at weaning (PND 23) and peri-pubertal 
(PND 48) time-points. As an initial evaluation point, carmine stained whole mounts were 
evaluated for developmental growth patterns in comparison with controls. Mammary glands 
were assessed a qualitative developmental score based on: longitudinal growth, lateral 
growth, presence of terminal end buds (TEBS), number of terminal ends, branching density 
and bud formation separately based on age and sex [28]. Male mammary gland assessment 
was more difficult than the females due to a male specific phenomenon where the 5
th
 gland 
was missing entirely in the fat pad. In this study, 52% of males were missing the 5
th
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mammary gland. This effect is independent of treatment and to our knowledge is an HSD-
specific issue. VOC exposure resulted in higher developmental scores in the males at PND 
23 and PND 48 and females at PND 48 in both VOC exposure groups, compared to controls. 
Developmental scores cannot be compared across time points or sexes, as the criteria for 
developmental assessment shifts between time points and the sexes. Developmental scores 
for glands can be found in Table 4.3. Mammary glands of VOC-exposed rats at weaning 
(PND 23) appeared larger in size, had more terminal end buds (TEBs), increased branching, 
and increased epithelial growth in both males and females at both 5X and 10X concentrations 
(p=0.03 and 0.03 respectively). At PND 48, all dosed mammary glands had increased side 
branching density, bud density and decreased number of TEBs compared to controls. 
Mammary glands of both 5X and 10X exposed females (p= 0.0004 and < 0.0001 for 5X and 
10X dosed females, respectively) and males (p= 0.02 and 0.0002 for 5X and 10X dosed 
males, respectively) were significantly more developed than the controls (Fig. 4.1 and Fig. 
4.2).  
VOC exposure does not change sex hormone receptor population 
 Immunohistochemical (IHC) staining of mammary gland sections for ERα, PR and 
AR were evaluated in both male and female glands. To quantify the levels, sections were 
evaluated for epithelial nuclear expression and given a Quickscore, as described in Chapter 2 
[29]. As seen in Chapter 2, ERα and AR expression in the HSD rat showed significant 
cytoplasmic staining and made evaluation of nuclear staining difficult. PR was not present in 
male mammary glands at any time point. There were no differences in androgen, estrogen or 
progesterone receptor expression in mammary epithelium at PND 23 or 48 (data not shown).  
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VOC and overall non-mammary gland effects 
 At necropsy, there were no significant body weight differences between DMBA-
treated control (317g±9), 5X (302g±8) or 10X (308g±6) females. There was a significant 
body weight difference between DMBA-treated and DMBA-untreated 10X (290g±4) females 
(p=0.01), which may have been due to the tumor burden in DMBA-treated females. DMBA-
treated 5X(491g±6) and 10X(481g±11) males has a statistically significant lowered body 
weight than the DMBA-treated control (513g±8) males (p=0.04 and 0.03, respectively). 
There was no difference between the DMBA-treated and DMBA-untreated 10X (494g±8) 
males. There were a few tumors that developed outside of the mammary gland and included: 
1 hemangioma (control male), 1 nephroblastoma (control female), 1 skeletal muscle sarcoma 
(control female), 1 squamous cell carcinoma (10X female) and 9 Zymbal’s gland tumors (3-
control males, 1-control female, 1-5X male, 1-5X female, 2-10X males and 1-10X female) 
(data not shown).   
VOC exposure was associated with an increased incidence of adenocarcinoma arising in 
fibroadenoma. 
In this study, mammary tumors began to appear 9 weeks after carcinogen 
administration.  Nine control female offspring, five female offspring in the 5X exposure 
group, five female offspring in the 10X exposure group and five male offspring in the 10X 
exposure group, that were also treated with DMBA, died due to mammary gland tumor 
burden during the 26 weeks post-carcinogen. Two additional males were found dead for 
unknown reasons (no diagnosis; hemorrhagic lungs) before the end of the study. There were 
no clinical findings of toxicity or tumor burden in any tissue in the males and females 
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exposed to 10X VOC and not treated with DMBA (data not shown). For ease of description, 
all further discussion will focus only on animals that received VOC exposure and DMBA.  
Female and male rat mammary tumor incidences are listed in Table 4.4. Fig. 4.3 
shows a representative image of the most common tumor types in this study: fibroadenoma 
(Fig. 4.3A-B), adenocarcinoma (Fig. 4.3C-D) and adenocarcinoma arising in fibroadenoma 
(Fig. 4.3E-F). Mammary tumor incidences found in females and males that died before the 
end of the study are listed in Table 4.5 and the tumor incidences of female and male 
survivors to necropsy in Table 4.6. Overall, 92% of control females and 27% of control 
males developed DMBA-induced mammary tumors by 30 weeks of age in this study. 
Historical data on spontaneous tumor development in HSD rats reported 90% of females and 
5% of males developed some type of mammary tumor by 104 weeks [30]. In the female rats 
in the current study, 42% in the control dose, 41% in the 5X dose and 50% in the 10X dose 
developed DMBA-induced malignant (“adenocarcinoma”, “adenocarcinoma, multiple” or 
“adenocarcinoma arising in fibroadenoma”) mammary tumors. 0%, 0% and 8% of  control, 
5X and 10X dosed males developed malignant tumors, respectively. Of the spontaneous 
tumors reported at 104 weeks of age, 15% of the females (12% adenocarcinomas and 3% 
adenocarcinomas arising in fibroadenomas) and none of the males developed malignant 
tumors [30]. There was no increase in overall tumor incidence due to VOC exposure in the 
females or males. An unusual mammary lesion was found in the male and female rats; an 
adenocarcinoma arising within a fibroadenoma. There was a dose dependent trend of 
increasing incidence of adenocarcinoma arising in a fibroadenoma in the female rats, 
however the difference in incidence between 10X vs control did not reach significance. There 
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were no statistical increases or trends in the male rats, however two incidences of 
adenocarcinomas in males were discovered in the 10X dose group. 
VOC exposure potentially shifts tumor latency in females. 
 The latency to tumor formation is shown in Fig. 4.4. Rats underwent weekly 
mammary palpations where approximate size, location and date were recorded. There was a 
shift towards a decreased tumor latency in the 5X and 10X females that did not reach 
significance. There was no significant difference between control and treated males on 
overall time to tumor formation.  
VOC exposure does not increase multiplicity of tumor formation. 
  In the animals that formed tumors, the number of tumors per animal was evaluated. 
Overall, mammary tumor multiplicity was not affected by VOC exposure in male or female 
rats (Fig. 4.5A-B). Of the rats that developed tumors, females had an average of 5-6 tumors 
per animal and males had an average of 2 tumors per animal. Of the females that developed 
benign tumors (“fibroadenoma”, “fibroadenoma, multiple”, “fibroadenoma with atypia”, or 
“fibroma”) an average of 4-6 tumors developed per animals (Fig. 4.5C). Of the females that 
developed malignant tumors, there was an average of 2 tumors per animals (Fig. 4.5D). In 
the control group, 46% of the female offspring that developed tumors had both 
fibroadenomas and adenocarcinomas. In the VOC treated groups, 45% and 55% of the 
female offspring in the 5X and 10X exposure group, respectively, developed both 
fibroadenomas and adenocarcinomas. 
Immunohistochemistry of malignant tumors for ER and PR staining 
 A subset (n=28) of adenocarcinomas and adenocarcinomas arising in fibroadenoma 
were immunostained for ERα and PR. 62% of tumors from female rats were ER-negative and 
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PR-positive (Fig. 4.6A-B) and 38% were ER-positive and PR-positive (Fig. 4.6C-D). The 
two malignant tumors from male rats (one adenocarcinoma and one adenocarcinoma arising 
from fibroadenoma) were both ER-negative and PR-negative (Fig. 4.6E-F). All of the female 
adenocarcinomas outside of fibroadenomas (n=11) were ER-negative while 67% (n=15) of 
female adenocarcinomas arising in fibroadenoma sampled were ER-positive. 
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Discussion  
The present studies demonstrate that exposure to VOCs during mammary gland 
development (GD 12- PND 48) at drinking water doses (and no inhalation exposure) only 5 
or 10 times higher than concentrations found in domestic well water are sufficient to produce 
accelerated mammary gland development in HSD rats. The highest dose of VOCs (10X) 
transiently lowered body weight and relative liver weights of both males and females at PND 
48, yet accelerated mammary gland development. Developmental exposure to the lower 
concentrations of VOCs resulted in higher mammary gland developmental scores compared 
to controls at perinatal (PND 23; male only)and peripubertal (PND 48; male and female) 
time-points. These data suggest that prenatal exposure to VOC may alter mammary gland 
development in HSD rats at doses lower than investigated here. Additionally, effects on 
mammary tissue were observed at doses of VOC (5X) lower than those required to exert an 
effect on body and liver weight.  Those findings implied that in HSD rats, the mammary 
gland was more sensitive to developmental VOC exposure than body or liver weight loss.  
The developmental scores of the mammary glands reveal a surprising VOC-induced 
acceleration in mammary gland development. The male mammary glands were more 
sensitive to VOCs at PND 23 than females. Both of the VOC exposed male groups had 
increased budding and an increased number of TEBs present in mammary glands at PND 23. 
The male mammary glands at PND 48 also had an overall increased density in both dose 
groups with some conversion to lobuloalveolar epithelial structures, usually only found in 
sexually mature male rat mammary glands (as demonstrated in Chapter 2). Exposure to 
estrogenic compounds have been shown to progress prepubertal development of the 
mammary gland in males and female rats [14]. None of the VOC in these studies are 
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considered estrogenic compounds, suggesting  at low doses the mixture of VOCs can disrupt 
endocrine pathways in the mammary gland or an unknown, non-endocrine disrupting 
mechanisms of action is responsible for these mammary gland perturbations; either way, 
further mechanistic investigations are required. Previous studies have shown that the male 
mammary gland is one of the most sensitive markers for EDCs and can be more sensitive 
than female mammary glands [14, 31,32]. Variations in the female mammary gland, such as 
number of TEBs, can be high and make detecting changes difficult [14]. However, the male 
has low variation in TEBs and is more sensitive to estrogenic compounds [14, 31]. These 
findings suggest that male mammary glands are also more sensitive to non-estrogenic effects 
than female mammary glands at PND 23. On PND 48 however, male and female mammary 
glands are both sensitive to mammary gland effects of non-estrogenic chemicals. 
An established risk factor for breast cancer is precocious puberty, which includes 
early age of breast development and menarche [33].  Since 1940, there has been an increased 
trend toward earlier breast development onset and menarche and a rise in EDCs in the 
environment may be responsible for this trend[34]. In utero and neonatal exposure to EDCs 
such as DES and BPA have been shown to permanently change mammary gland 
development and are associated with an increased risk of developing pre-neoplastic lesions 
and breast cancer [20, 35-38]. VOCs, when tested at levels much higher than these studies, 
are not reported to be strong EDCs. Some endocrine disrupting activity in women have been 
associated with PERC exposure. Lower levels of VOC exposure, may be able to disrupt 
endocrine pathways in a non-monotonic manner.  EDCs have also been shown to induce 
epigenetic changes and are linked to increased breast cancer risk [20]. EDCs, like TCDD and 
BPA, have also been found to induce epigenetic change in the germline and promote early-
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onset female puberty transgenerationally [39]. Benzene, metabolites of PERC and TCE, and 
VC alter DNA methylation [40-42].  Further investigation may reveal VOCs-induced 
epigenetic changes can result in accelerated mammary gland development.  
The second half of these studies compares the responses of mammary glands of male 
and female HSD rats to developmental exposure to 5X and 10X VOCs via drinking water 
and a “second hit” with DMBA, a mammary specific carcinogen. The data in the present 
study indicate that exposure during mammary gland development to VOC contaminated 
drinking water, close to the range of human exposure, did not result in overall significantly 
increased DMBA-induced mammary tumorigenesis. However, several interesting findings 
are worth noting. With VOC exposure, there was a significantly increased trend in the 
incidence of malignant adenocarcinoma arising from fibroadenoma in the female rat. While 
this is a rare occurrence in humans, it is not an uncommon lesion in rats [43-45]. No previous 
evaluations of mammary gland for these VOCs have been known to induce these specific 
mammary tumors in rats during 2 year bioassays [2-5]. An epidemiological study has 
reported a slightly elevated breast cancer risk for women who were highly exposed to PERC 
in the drinking water [46]. In the males, all the early deaths due to tumor burden and the only 
two males that developed adenocarcinomas were in the high VOC exposure group. 
Malignant tumors have not been reported in 2 year spontaneous tumor studies in male HSD 
rats [30]. Further testing with low levels of oral and inhalation exposure to a mixture of 
VOCs may exert a stronger effect on mammary tumor development in both males and 
females.   
  Breast cancer is a heterogeneous disease with a growing number of subtypes. 
Prognosis and treatment for the different subtypes differ and primarily depend on the 
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expression of hormone receptors ER and PR as well as human epidermal growth factor 
receptor-2 (HER2). The main subtypes are luminal A (ER-positive and/or PR-positive, 
HER2-negative), luminal B (ER-positive and/or PR-positive, HER2-positive), basal-like 
(ER-negative, PR-negative, HER2-negative) and HER2+ (ER-negative, PR-negative, HER2-
positive). The percentages of each subtypes in The Carolina Breast Cancer Study were 51%-
luminal A, 16%-luminal B, 20%-basal-like, 7%-HER2-positive and 6% unclassified [47]. 
Data from the California Cancer Registry revealed, 82% of the male breast cancers were ER-
positive and/or PR-positive, 15% were HER2-positive and 4% were negative for all three 
(basal-like) [48]. Luminal A has the best prognosis of all the subtypes and basal-like and 
HER2-positive subtypes have the worst [49]. The ER and PR staining of the malignant 
tumors treated with vehicle or VOCs demonstrated the tumors from females were either 
luminal A or B and the two tumors from the males were either basal like or HER2+. 73% of 
luminal (A and B) tumors in women were ER-positive and PR-positive and only 11% were 
ER-negative and PR positive [47]. In VOC treated female rats, ER-negative and PR-positive 
tumors were more common (62%) than ER-positive and PR-positive (38%). All of the female 
AC sampled were ER-negative while 67% of female AC arising in FA sampled were ER-
positive. Since ER-positive/PR-positive cancers are more common in women, the AC arising 
in FA may be more human relevant. The lack of PR expression in the male malignant tumors 
may suggest that these are basal-like or HER2+ tumor types. There may be a species-related 
effect due to the fact that male rat mammary epithelium have no PR present throughout their 
lives while human males do have PR expression in the mammary glands [50]. BRCA1 
mutations are associated with the basal like breast cancer phenotype [51]. 
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Immunohistochemical markers for HER2 will allow for the differentiation of the further 
tumor subtypes; luminal A or B and basal-like or HER2+.  
DMBA is the most commonly used mammary specific tumor initiator used in 
Sprague Dawley rat model [51]. N-methyl-N-nitrosourea (NMU) is also commonly used in 
Sprague Dawley or Fischer 344 rat model. DMBA is given by gavage and is metabolized by 
the liver to its reactive form, while NMU is given by subcutaneous injection and is a direct 
acting mammary carcinogen. Both compounds yields tumors with similar latency and 
incidence [51]. DMBA was selected over NMU for its wide use in rats, thus increasing 
background information that might be gathered in male and female rats, and our laboratory’s 
familiarity with the compound. NMU induces a higher ratio of adenocarcinomas than DMBA 
[52]. Concerns about impaired liver metabolism affecting the efficacy of DMBA were 
alleviated when low levels of VOCs were not seen to affect CYP mRNA levels in Chapter 3 
and it was estabilished that DMBA and VOCs are metabolized by varying types of CYPs [2-
6,53].  
There was an issue with DMBA sensitivity in this study (though NMU would have 
more than likely had the same issue). The females were highly sensitive to mammary tumor 
formation. This all may have to do with the timing of administration of the carcinogen. PND 
30 was selected to target the life stage when the mammary gland TEBs were most plentiful, 
as this is a window of susceptibility. DMBA has historically been given on PND 45 in other 
rat strains to induce mammary gland tumor formation. Because HSD rats mammary glands 
grow at an accelerated rate naturally and TEBs are at their peak around PND 30 in control 
animals, we dosed much earlier. Over 92% of the control females developed tumors. A 
significant increase in total tumor formation in treated animals cannot be detected with that 
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high of a background rate. When divided into benign and malignant tumor formation, 46% of 
the control females developed malignant tumors and there was a 10% increase in malignant 
tumor formation in the 10X females. Perhaps a higher n is needed to statistically see a 
modest increase in tumor formation. In future studies with this rat strain, DMBA should 
either be given at a lower dose or a less sensitive time point to avoid a high tumor burden in 
controls. Although the males are sensitive to disruption of early mammary gland 
development, they are not sensitive to DMBA initiation of cancer. Only 27% of control 
males developed tumors and 30% in the high VOC exposure. Also, 2 males developed 
malignant tumors and they both died early due to their mammary tumor burden. A higher 
dose of DMBA, spread over time may induce more tumor formation, or a longer period after 
DMBA dosing may allow for more adenocarcinoma arising from a fibroadenoma to occur.  
The rapid development of the mammary gland due to VOC exposure seen early in life 
could mean the mammary gland is protected from administration of a tumor initiator. The 
long term harmful effects of accelerated mammary gland development are potentially 
masked by the short term protection from a shorter window of susceptibility. The TEBs in 
VOC exposed mammary glands develop and differentiate into terminal ends faster than the 
controls. When DMBA was administered, the control rat mammary glands have more TEBs 
present, making them more sensitive to DMBA. Further mechanistic studies on the mode of 
action of non-estrogenic mammary gland acceleration could reveal alternative risks for VOC 
exposed mammary glands. 
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Table 4.1 Female weight indices of offspring from the VOC drinking water exposure 
study. 
  PND 23 (n)    PND 48 (n) 
Body Weight (g)   
     Control 55.03 ± 0.91 (11) 173.0 ± 1.85 (12) 
     5X 54.82 ± 1.28 (12) 169.2 ± 2.22 (11) 
     10X 53.07 ± 1.42 (9) 163.4 ± 2.52** (12) 
Absolute Liver Weight (g)    
     Control 2.45 ± 0.05 (11) 9.57 ± 0.19 (12) 
     5X 2.38 ± 0.08 (12) 9.13 ± 0.18 (11) 
     10X 2.39 ± 0.08 (9) 8.54 ± 0.20** (12) 
Relative Liver Weight     
     Control 0.045 ± 0.001 (11) 0.055 ± 0.001 (12) 
     5X 0.043 ± 0.001 (12) 0.054 ± 0.001 (11) 
     10X 0.045 ± 0.001 (9) 0.052 ± 0.001** (12) 
Note: VOC= volatile organic compound. PND= postnatal day. 5X and 10X= 5-fold and 10-
fold water contamination measured at Camp Lejeune [26]. Data presented are mean ± SE; n 
= 9-12 animals/treatment group. ** indicates p < 0.01 compared with control by Student’s t-
test.  
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Note: VOC= volatile organic compound. PND= postnatal day. 5X and 10X= 5-fold and 10-
fold water contamination measured at Camp Lejeune [26]. Data presented are mean ± SE; n 
= 11-12 animals/treatment group. ** indicates p < 0.01 and *** indicates p < 0.001compared 
with control by Student’s t-test.  
. 
 
 
 
  
Table 4.2 Male weight indices of offspring from the VOC drinking water exposure study. 
       PND 23 (n)       PND 48 (n)  
Body Weight (g)    
     Control 58.58 ± 1.07 (12) 221.8 ± 2.37 (12) 
     5X 57.69 ± 0.81 (12) 216.6 ± 2.32 (12) 
     10X 59.07 ± 1.17 (12) 210.0 ± 3.28** (11) 
Absolute Liver Weight (g)    
     Control 2.67 ± 0.05 (12) 13.11 ± 0.36 (12) 
     5X 2.56 ± 0.07 (12) 12.58 ± 0.26 (12) 
     10X 2.70 ± 0.08 (12) 11.41 ± 0.24*** (11) 
Relative Liver Weight     
     Control 0.046 ± 0.001 (12) 0.059 ± 0.001 (12) 
     5X 0.044 ± 0.001 (12) 0.058 ± 0.001 (12) 
     10X 0.046 ± 0.0004 (12) 0.054 ± 0.001** (11)  
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Table 4.3 Mammary gland developmental scores from VOC drinking water exposure study. 
                   Females Males   
   PND 23 (n)   PND 48 (n)   PND 23 (n)   PND 48 (n) 
Control 2.3 ± 0.2 (12) 1.9 ± 0.2 (12) 2.1 ± 0.3 (12) 2.3 ± 0.2 (12) 
5X 2.4 ± 0.3 (12) 3.0 ± 0.2** (11) 2.9 ± 0.2* (12) 3.0 ± 0.1* (12) 
10X 2.9 ± 0.3 (12) 3.2 ± 0.2** (12) 3.1 ± 0.3* (12) 3.5 ± 0.1** (12) 
Note: VOC= volatile organic compound. PND= postnatal day. 5X and 10X= 5-
fold and 10-fold water contamination measured at Camp Lejeune [26]. Data 
presented are mean ± SE; n =11-12 animals/treatment group. * indicates p < 
0.05 and ** indicates p < 0.01 compared with vehicle control by Student’s t-
test. 
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Table 4.4 Mammary gland tumor incidences 
                                                         Females Males 
 Control 5X 10X Control 5X 10X 
FA 5 6 4 2 2 1 
FA, Multiple 18 16 14 4 0 5 
FA with Atypia 2 3 2 0 0 0 
Fibroma 0 0 1 1 1 0 
AC 2 0 3 0 0 1 
AC, multiple 3 3 1 0 0 0 
AC arising in FA 6* 8 11 0 0 1 
 n=26 n=27 n=24 n=26 n=26 n=26 
Note: VOC= volatile organic compound. FA= fibroadenoma. AC=adenocarcinoma.            
5X and 10X= 5-fold and 10-fold water contamination measured at Camp Lejeune [26].                     
Some animals had multiple tumor types and are represented more than once. * indicates                     
a significant trend p < 0.05 by Cochran-Armitage trend test. 
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Table 4.5 Early death tumor incidences 
                                                         Females Males 
 Control 5X 10X Control 5X 10X 
FA 2 0 1 0 0 0 
FA, Multiple 5 5 3 0 0 1 
FA with Atypia 0 0 0 0 0 0 
Fibroma 0 0 0 0 0 0 
AC 2 0 3 0 0 1 
AC, multiple 3 3 1 0 0 0 
AC arising in FA 1 2 2 0 0 1 
 n=9 n=5 n=5 n=0 n=0 n=5 
Note: VOC= volatile organic compound. FA= fibroadenoma. AC=adenocarcinoma.             
5X and 10X= 5-fold and 10-fold water contamination measured at Camp Lejeune [26].                     
Some animals had multiple tumor types and are represented more than once. 
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Table 4.6 Survivors to study end tumor incidences  
                                                        Females Males 
 Control 5X 10X Control 5X 10X 
FA 3 6 3 2 2 1 
FA, Multiple 13 11 11 4 0 4 
FA with Atypia 2 3 2 0 0 0 
Fibroma 0 0 1 1 1 0 
AC 0 0 0 0 0 0 
AC, multiple 0 0 0 0 0 0 
AC arising in FA 5 6 9 0 0 0 
 n=17 n=22 n=19 n=26 n=26 n=22 
Note: VOC= volatile organic compound. FA= fibroadenoma. AC=adenocarcinoma. 5X and 
10X= 5-fold and 10-fold water contamination measured at Camp Lejeune [26].                     
Some animals had multiple tumor types and are represented more than once. 
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Figure 4.1 Female offspring mammary gland whole mounts in developmental VOC 
exposure study. (A-C) PND 23 0.8x. (D-F) PND 48 2x. Statistically increased 
developmental scores were achieved at PND 48, in the dose groups 5X (E) and 10X (F), with 
increased branching density compared to control (D). n =11-12 animals/treatment group. 
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Figure 4.2 Male offspring mammary gland whole mounts in developmental VOC 
exposure study. (A-C) PND 23 0.8x. (D-F) PND 48 2x. Statistically increased 
developmental scores were achieved at both PND 23 and PND 48, in both the dose groups 
5X (B and E) and 10X (C and F), with increased budding branching density compared to 
controls (A and D), respectively. n = 12 animals/treatment group. 
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Figure 4.3 Representative images of a fibroadenoma, an adenocarcinoma and an 
adenocarcinoma arising in a fibroadenoma from DMBA induced tumor study. 
Fibroadenomas were variably sized, well defined nodular masses that were often 
encapsulated and compressed the adjacent mammary tissue (A) 2X (B) 20X. 
Adenocarcinomas were less circumscribed and often invaded the surrounding adipose tissue. 
The neoplastic epithelial cells formed densely packed acinar structures that were several 
layers thick. (C) 2X (D) 40X. Adenocarcinoma arising in fibroadenoma was described as a 
focally adenocarcinomatous change within a well-defined primary fibroadenoma (E) 2X (F) 
10X, (adenocarcinoma, arrow).  
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Figure 4.4 Latency of palpable tumors in female and male offspring from DMBA 
induced tumor study. Female (A) and male (B) tumors present in animals at necropsy that 
were not detected by palpation were censored. 
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Figure 4.5 Tumor multiplicity in female and male offspring from DMBA induced tumor 
study. Total tumor multiplicity in tumor bearing females (A) and males (B) in developmental 
VOC exposure study with DMBA tumor initiation. 100% of tumor bearing control and 5X 
females and 91% of the tumor bearing 10X female had benign tumors present (C). 46%, 45% 
and 55% of control, 5X and 10X females, respectively, had both benign and malignant 
tumors develop and 9% of 10X females had only malignant tumors form (D). 
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Figure 4.6 Immunohistochemical staining of adenocarcinomas with ERα and PR. 
Adenocarcinoma from a control female containing negative cells for ERα (A) and positive 
cells for PR (B) 40x. Adenocarcinoma arising from a fibroadenoma from a control female 
containing positive cells for ERα (C) and PR (D) 40x. Adenocarcinoma from a 10X male 
containing negative cells for ERα (E) and PR (F) 40x. 
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CHAPTER 5: Conclusions and Perspectives 
Novel Findings 
  In thinking about the question “Could prenatal/neonatal VOC exposure from drinking 
water potentially increase the susceptibility of men to develop breast cancer?”, several data 
gaps needed to be investigated. The first was to address data gaps in mammary gland 
development in the rodent model of choice, the HSD rat. Chapter 2 has produced data that 
characterized normal and abnormal morphological mammary glands from mammary bud 
development to sexually mature mammary glands in the male and female HSD rat. The major 
novel findings are: 1) the differences, but more so the similarities, between the male and 
female HSD rat mammary gland development and 2) the HSD strain sensitivity to EDCs.  
  The similarities between male and female rat mammary gland development have not 
been extensively studied, especially in the HSD rat strain. The most important similarity is in 
the overall mammary architecture and cellular morphology during early life through puberty 
time points. From before birth until puberty, male and female mammary glands, and 
especially the mammary epithelium, are virtually indistinguishable. The mammary gland 
starts out the same in males and females with mammary bud formation on E15.5. Ductal 
elongation continues in both sexes for the duration of gestation and at birth, the mammary 
epithelium have formed ductal trees. Isometric mammary gland development continues 
during neonatal and prepubertal time points in both sexes, with TEB development by PND 
21. Before puberty both male and female mammary epithelium has a tubuloalveolar 
  
morphology. All of these features are in line with male and female breast development in 
humans. 
  Despite the many similarities there is still more differences between the male and 
female rat than there are in humans. Sexual dimorphism begins in the rat on E18.5. An 
androgen surge in the males induces apoptosis and the connection between the mammary 
epithelium and the epidermis begins to atrophy in the males [1]. The female gland continues 
to develop nipples while the males do not. The second instance of sexual dimorphism is 
during puberty when the female mammary epithelium undergoes exponential growth to fill 
the fat pad, while growth of the male mammary epithelium abruptly stops before the edges of 
the fat pad. This characteristic is also shared with humans. The final major difference 
between males and female rats occurs in the mature mammary glands. Females keep the 
tubuloalveolar mammary epithelial morphology while the males develop a lobuloalveolar 
morphology. This is the most important difference between male rats and humans. Human 
male mammary epithelium is structurally similar to females at all ages but is just considered 
a rudimentary form of the female breast [2].  
  Prenatal EDC exposures can adversely affect mammary gland development, impact 
lactation and ultimately may be carcinogenic [3,4]. To address the HSD strain sensitivity to 
EDCs, diethylstilbestrol (DES) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) were used 
in hopes of demonstrating accelerated and delayed mammary gland development. In other rat 
strains, prenatal exposure to DES and TCDD have been shown to accelerate or delay, 
respectively, mammary gland development and increased risk of mammary tumor formation 
later in life [5-9]. In the HSD rat, prenatal TCDD treatment also delayed mammary gland 
development in both the male and female offspring. The mammary glands of females treated 
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with TCDD never recovered from the developmental delays, as evidenced in mammary 
whole mounts, suggesting a potentially permanent effect of this pollutant on the mammary 
gland. By young adulthood (70 days old), the mammary glands of male TCDD-exposed 
offspring appeared more similar to controls than they had at earlier life stages. It is possible 
that because the mammary gland of the male becomes dense very quickly, due to 
lobuloalveolar development, differences were difficult to discern in the male.  
  Surprisingly, the DES treated males and females did not have the expected 
accelerated mammary gland development compared to the controls. The HSD rat has an 
already accelerated mammary gland development when compared to other strains such as the 
Long Evans (LE) or the Charles River Sprague Dawley (CRSD) [10-11]. The rate of 
mammary gland development is not dependent on the animal’s size as previously thought 
[11].The HSD rat is significantly smaller than both the LE and CRSD, yet has an accelerated 
development of the mammary epithelium compared to these other strains. DES has been 
shown to accelerate mammary gland development in other rat strains [5,12], but failed to 
affect HSD mammary gland development at the dose tested. Previous studies injected the 
compound subcutaneously and higher levels of DES were used in weanling rats. In the 
present study, the dams received the compound by oral gavage during late pregnancy. Lower 
doses of DES were used to avoid maternal or fetal overt toxicity. The lack of DES 
acceleration of the mammary gland development in the HSD rat strain may be due to the 
different dose of DES used, route of exposure, or rate of mammary gland development 
between rat strains. DES-exposed male rats at PND 70 retain some of the tubuloalveolar 
morphology found in female and immature male glands. DES treated males may have been 
feminized, or more likely, the mammary epithelium exhibited a delay in maturation 
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compared to the control or TCDD treated animals. Similar exposures with later adulthood 
timepoints would clarify this question.  
  The second data gap that needed to be addressed was how were the half-lives and 
body burdens of VOCs affected when given as a mixture of several VOCs in 
pregnant/lactating HSD dams and the resulting offspring. The reactive metabolites formed 
from the individual components of the VOC mixture are largely dependent on dose and route 
of exposure [13]. High dose inhalation studies might not form the same metabolites as a low 
dose drinking water studies. Embryogenesis and puberty are windows of susceptibility for 
the mammary gland [14]. Most toxicokinetic studies in females are in nulligravid adult 
animals and do not capture these sensitive time points. The half-lives of the VOCs in the 
blood when given as a mixture at GD 15 were similar to half-lives of each chemicals given as 
a single exposure [15-18]. Additionally, the VOC were detected in the mammary gland and 
in the fetus, demonstrating that in utero and potentially lactational exposure can occur. 
  The drinking water body burden study that demonstrated that even with unlimited 
access to VOC contaminated drinking water, the dams and offspring never drank enough 
volume or consistently enough for the VOC to accumulate or reach a steady state in the 
blood. The episodic, low dose nature of the mixture exposure made this portion of the studies 
difficult to interpret. The VOCs are eliminated from the rat quickly and most drinking water 
consumption occurs at night [19]. Necropsies took place at 9:30-10:00AM meaning the lights 
were on for 2.5-3 hours and drinking water consumption would have been reduced at this 
time. The amount of water consumed in one sitting and the time from last exposure cannot be 
determined. Surprisingly the levels of benzene in the blood of both dams and pups, compared 
to the other chemicals in the mixture, were much higher than anticipated. Benzene has been 
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shown to induce mammary tumors in mice at very high doses in a 2-year bioassay in mice 
[20]. The data suggests that benzene behaves differently when part of a mixture at low doses 
and deserves further examination. Both the half-life and drinking water concentrations of 
benzene and TCE are similar in the VOC mixture, yet the amounts of benzene in the blood 
are significantly higher than TCE and trans-1,2-DCE. VC could not be detected in the blood, 
as our collaborators at the Center for Disease Control only had assays developed for urinary 
assessment of VC. Because of the volatile nature of the chemicals tested, the matrix in which 
they were measured had to be collected under hermetic conditions and we were unable to 
perform this type of collection for urine and serum form the same animal. Due to these 
limitations, the half-life of VC in the pregnant dam and body burden concentrations in the 
fetus remain unknown. 
  With the knowledge gained from Chapters 2 and 3, the effects of VOCs on mammary 
gland development and susceptibility to carcinogens could be addressed. The effects of VOC 
on mammary gland development has not been previously studied because until recently, the 
mammary gland was not a mandatory tissue for evaluation in test guidelines studies unless 
female tumors were visually evident at necropsy [21]. The focus of Chapter 4 was to 
investigate the effects of a mixture of VOCs on the mammary glands of HSD rats. I 
hypothesized that early life exposure to this mixture may result in increased altered 
mammary gland development and ultimately increased tumor development in male rats with 
secondary exposure to the mammary gland carcinogen, dimethylbenz-a-anthracene (DMBA). 
  To determine the effects on early mammary gland development, VOC exposure 
began in utero, before the development of the mammary gland bud and continued until 
necropsy. This exposure paradigm insured the mammary gland was constantly exposed to 
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human relevant levels of VOC throughout development, through either transplacental 
transfer, lactation or ingesting treated drinking water. Just after weaning, male mammary 
gland development was significantly accelerated at both the low and high VOC 
concentrations tested. The VOC-exposed females also had mammary development that 
appeared accelerated compared to the controls, but did not reach significance. At PND 48, 
peri-pubertal male and female rats have accelerated mammary gland development after both 
low and high VOC exposures. The mammary glands from VOC-exposed animals were more 
densely branched and larger in epithelial area. Additionally, the mammary glands of VOC-
exposed males appeared to have started converting to a lobuloalveolar morphology at PND 
48, an indication that they were prematurely transitioned to a sexually mature gland. 
Mammary gland acceleration was an unexpected outcome in this study. Previously in 
Chapter 2, the HSD rats were not sensitive to mammary gland acceleration by DES. But, the 
DES insensitivity could be a dose-related issue. While this is a novel finding, it suggests that 
the already accelerated mammary gland development of HSD rats are susceptible to further 
mammary gland accelerations and that the 10 μg/kg DES doses during gestation were not 
enough to accelerate mammary gland development. In trying to avoid maternal and fetal 
toxicity, the dose was too low to affect mammary gland development in this strain. DES 
given at higher doses after birth in addition to the gestational exposure would likely induce 
the accelerated mammary gland development excepted and the HSD strain may be less 
sensitive to EDCs during gestation alone. 
  The majority of the VOC-exposed and control rats of both sexes were dosed with 
DMBA or vehicle at PND 30 to initiate mammary gland tumor development. DMBA was 
chosen over NMU primarily because it a very commonly used model for mammary gland 
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tumorigenesis in rats [22]. Typically, this exposure to carcinogen would have been on PND 
45 or 50, as reported for other rat strains [6, 24]. However, during the course of these 
experiments, it came to my attention that mammary gland development occurs earlier in this 
rat strain, therefore I needed to target a time when control glands might still contain TEBs, 
the known targets for carcinogen action [24]. The study design was finalized and DMBA had 
been delivered before we knew that the VOCs caused an even more accelerated breast 
development than in the controls, modifying even our best efforts to target those cells.  
  The males and females continued on VOC-laced drinking water exposure until PND 
48 and were then switched to water without VOC contamination. The animals were 
monitored for tumor development and underwent full necropsy 26 weeks after they were 
dosed with DMBA (about 30 weeks of age). The major findings of this study indicate that: 1) 
a rarely diagnosed tumor type in the mammary gland seems to be much more common in 
HSD rats; the adenocarcinoma arising in a fibroadenoma, 2) in females, VOC exposure was 
associated with a statistically significant increased trend in the incidence of adenocarcinomas 
arising in a fibroadenoma, 3)  two males developed adenocarcinomas and both were in the 
high VOC concentration group and 4) DMBA induced mammary tumors in this study 
produced different molecular subtypes. 
  The increased trend in adenocarcinomas arising in fibroademona is an interesting 
finding since these tumors were typically found in older rats. All the rats that developed 
adenocarcinomas outside of fibroadenomas died early in this study. Fibroadenomas are 
considered benign tumors but are shown in the study to potentially convert over time to a 
malignant phenotype. Suggesting that the fibroadenomas are accumulating additional 
mutations as the animals aged and inducing an adenocarcinomatous change. There was a 
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difference between the immunophenotype between the adenocarcinomas and the 
adenocarcinomas arising in fibroadenomas.  
  All of the tested female tumors were found to be PR-positive, which makes them 
luminal-like (either luminal A or B). Only the adenocarcinomas arising in fibroadenomas 
were both ER-positive and PR-positive. IHC staining of the adenocarcinomas were all ER-
negative and PR-positive. These findings suggest that the DMBA-induced mutations for 
adenocarcinomas can be different from the mutations induced in fibroadenomas. The 
fibroadenomas may have accumulated additional mutations to become malignant but still had 
the some of the immunophenotypes of the surrounding fibroadenoma. ER-positive and PR-
positive tumors are the most common immunophenotype in women [25]. ER-negative and 
PR-positive is a rarer immunophenotype in women, but both cancer subtypes, being ER-
positive and/or PR-positive, are associated with a greater chance of survival in women [25]. 
ER-negative and PR-negative female rat tumors were not found in this study or in literature 
[26]. The two malignant tumors found in males were both ER-negative and PR-negative. 
This is a rare molecular subtype found in men, and is more commonly seen in individuals 
that carry the BRCA1 gene [27,28] HER2 staining will further differentiate the molecular 
subtypes and may reveal that the male rat tumors are the even rarer basal-like subtype. While 
IHC markers may not indicate that the rat tumors would behave exactly as they would in men 
and women, they will allow for further rat/human comparisons. 
  The question of whether or not prenatal/perinatal VOC exposure in drinking water 
could have made men more susceptible to development breast cancer is inconclusive in these 
studies. Several limitations could have an impact on this conclusion.   
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Limitations and conundrums 
  These studies focused on VOC drinking water exposure but has left out arguably the 
most important exposure route for the men and women at camp Lejeune; inhalation. VOCs 
off-gas very easily from water when exposed to air and humans are exposed to VOC via 
inhalation, oral and dermal absorption [15-18,29]. The inhalation chambers we had access to 
are set up for individual animal exposure to a single chemical exposure. The conundrum we 
ran into was wanting to have human relevant VOC exposure, meaning VOC exposure from 
gestation to the end of puberty, and not being about to expose litters to a mixture of VOC at 
once. The inhalation studies are not equipped to 1) house multiple animals (dam and pups), 
2) house pups in general (wire bottom cages), or 3) test exposure to a mixture of chemicals at 
the same time. Therefore it was decided to go with a drinking water only exposure. While the 
lack of an inhalation component in these studies is a limitation it may also suggest that the 
amount of VOCs humans were exposed to at Camp Lejeune could have been higher than the 
levels of exposure in the rats in these studies. The blood levels of the men and women at 
Camp Lejeune are unknown and the best that could be done was to as closely recapitulate 
VOC exposure. The 5X and 10X dose levels were chosen with a safety factor of at least 10 in 
mind. 
  There are several limitations in the VOC body burden data. The inability to collect 
VC under hermetic conditions in the urine means we know nothing about how it behaves in a 
mixture or in the pregnant rat. Although VC was present at very low concentration in the 
well water at Camp Lejeune and was likely the result of the natural break down of PERC and 
TCE, it is a potential mammary gland carcinogen. If the toxicokinetics of VC were affected 
by the mixture of VOCs in the pregnant rat that is something that was missed in this study. 
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   In trying to recapitulate human exposure data verses a study design with minimal 
unknowns was a constant challenge in these studies. We ultimately decided to be as human 
relevant as possible, which meant an ad libitum drinking water exposure body burden study. 
Some variables that came with an ad libitum drinking water exposure study made the body 
burden data difficult to assess. The fact that individual water consumption could not be 
determined due to the group housing of litters made determining an actual daily dose 
impossible. To get around this, conversion estimates had to be made that were less than ideal. 
Additional experiments are needed to focus less on human exposures and more on how a 
mixture of VOCs affect the individual chemical’s toxicokinetics. The second conundrum 
faced with using a human relevant mixture is that the active mixture component(s) are 
unknown. Testing the individual compounds or mixtures with fewer chemicals could reveal 
the active component or that it is the mixture is important. These studies may be important 
for future VOC assessment but are beyond the scope of this project. 
  A rodent model for male breast cancer has its limitations. Mice cannot be used since 
most male mammary epithelium is completely destroyed due to the androgen surge during 
embryogenesis [30]. The limitation in rats comes from the lobuloalveolar mammary 
epithelium of mature male rats, which is different compared to female rats and male and 
female humans. How the differences in mature male mammary epithelium affect the human 
relevance is unclear. Although the lobuloalveolar development of the male mammary gland 
makes development human relevant experiments more complex, the mammary glands during 
gestation and early life are very similar. The rat model for in utero and early life exposures to 
EDCs can be expected to be more human relevant, and alterations in male and female 
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mammary gland development early in life could potentially occur in both male and female 
children as well. 
Impact on science 
  Recent changes in the NTP test guidelines protocols have made the HSD rat 
mammary gland atlas an important, timely and useful document [31,32]. It is anticipated to 
be included in the NTP’s Non-neoplastic Lesion Atlas online, which is a highly used and a 
free resource for pathologists around the world. Both NTP pathologists and scientists 
working on the HSD rat strain will be able to use the mammary gland atlas to better 
understand normal and chemically altered mammary gland development, differences between 
species and protein patterns for steroid hormones known to have involvement in mammary 
gland development. Of particular importance are the comparisons that can be made to other 
rat strains. Knowing the innate strain differences in mammary gland development will allow 
for better strain selection for future mammary gland studies. The NTP and other institutions 
are including mammary gland whole mount production in their standard testing protocols in 
modified one-generation reproduction studies, reproductive assessment by continuous 
breeding studies and 2-year bioassays [32]. The challenge has been to incorporate evaluation 
of those collected glands as one of the major end products. The majority of current studies in 
the literature are based on strains other than HSD and, to my knowledge, strain differences in 
mammary gland development have not been previously reported. Differences in ratios of 
subtype tumor formation will also be useful information in strain selection. The HSD females 
do have more common, luminal subtype of mammary tumors and demonstrate their human 
relevance. Other strains may produce a different subtype or different ratios of the different 
subtypes.  
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  While the harmful effects of individual VOCs on numerous organ systems have been 
extensively studied, traditional toxicity testing with high dose, single daily oral exposure in 
adult animals leave large data gaps. Non-monotonic dose response, windows of susceptibly, 
and the effect of additive, synergistic, or antagonistic chemical interactions in mixtures are 
all missing from traditional testing. While these studies are not conclusive on the effects of 
VOCs on mammary gland development and susceptibility to carcinogenesis, they bring to 
our attention the need to accurately model future rodent studies to human relevant exposures 
of VOCs and all other potential environmental contaminates.  
Future studies 
  The recent change of preferential rat strain in the NTP now is using the HSD strain. 
This change in strain demands depth in understanding of the HSD mammary gland 
physiology. Some data gaps currently in the literature on mammary gland development in the 
HSD rat include: 1) a mechanism for the rapid mammary gland developmental rate of the 
HSD rat compared to other strains, 2) gene expression differences between the tubuloalveolar 
epithelium of mature females and immature male and the lobuloalveolar epithelium of 
mature males and 3) what influences (and how) mammary gland growth and development in 
males before and after puberty. Understanding the main drivers of the HSD’s accelerated 
mammary gland development would influence how future mammary gland testing is 
performed and evaluated. Examination of the major sexual dimorphism between male and 
female rat mammary glands could not only reveal the mechanism by which the male 
mammary glands develop compared to females but could discover important similarities and 
differences to human mammary gland development. An in depth comparison of hormone 
levels and receptor populations in the male mammary gland may elucidate the reasons for 
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differences in development and growth before and after puberty. Further studies on the male 
rat mammary gland could determine if the rat is an appropriate model for male breast cancer. 
Since radiation exposure increases the incidence of mammary tumor formation in both 
human and rat males, perhaps differences in adult mammary gland morphology/histology 
does not affect the human relevancy of male rat tumor formation.  
  The VOC assessment needs to focus on human relevant mixtures. The body burden 
data in Chapter 3 suggest potentially interesting toxicokinetics of benzene as a low dose 
mixture in rats. In revisiting the body burden studies in this project, knowing the average 
daily dose would be key. Although lactational exposure may be very important to the 
mammary gland developmental outcomes they make VOC body burden assessment very 
difficult. Future studies would benefit from singly house animals with water consumption 
recorded, ideally, in either pregnant animals or weaned offspring, to model sensitive 
subpopulations. Furthermore, VC in a mixture modeling is still needed. Methods of 
collecting urine under hermetic conditions are necessary. Anesthesia was not used in these 
studies avoid for any potential interactions with the VOCs, but may not impact VC analysis 
in the urine.  
  When administering a mammary gland carcinogen, timing is key. If the mammary 
gland is hit with a carcinogen when TEBs are at their peak abundance, tumor formation is 
highly likely. DMBA has historically been given to female rats at PND 45-50. In Chapter 4, 
DMBA was administered at PND 30 to male and female rats. The reasoning was that the 
HSD rat has an accelerated mammary gland development and VOCs further accelerate 
growth; if DMBA was administering at PND 45, the control rats would be nearing the ends 
of their window of susceptibility and VOC exposed rats would be even closer to the end. By 
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administering DMBA at PND 30 we were trying to assure that TEBs would be high in the 
mammary glands of both controls and VOC exposed. This resulted in nearly 96% of control 
females developing tumors, and many needing to be sacrificed well before 26 weeks after 
carcinogen exposure. The 5X and 10X VOC-exposed females had 81% and 92% tumor 
formation, respectively; the slightly lower tumor burden may be due to the mammary glands 
being more developmentally accelerated and fewer TEBs were present during DMBA 
administration. While in the males, there were very few animals with tumor formation by the 
end of the study. This may be because the male rat had far fewer TEBS than similarly aged 
females. Furthermore, the stem cells in the TEB are thought to be the eventual target of 
carcinogens, and it is not known if males have a programmed spike in mammary stem cells 
during mammary outgrowth as do females.  These results reveal that precise DMBA dosing 
for both males and female are needed for this strain of rat. Future studies should evaluate 
DMBA exposure for the optimal: 1) amount of carcinogen, 2) timing of administration and 3) 
length of time after administration is needed to elicit a moderate tumor response, in both 
HSD males and females. With a moderate tumor formation in control (vs the near 100% rate 
in this study), testing a chemical’s ability to initiate, promote or protect against cancer 
development will be easier to determine. Once a chemical is discovered to either delay or 
accelerate mammary gland development, further modification of carcinogen administration 
could determine if a chemical is shifting the window of susceptibility or causing a permanent 
change in the mammary gland that may predispose to or protect from tumor formation later 
in life.   
  The effects of developmental exposures to VOCs are not complete with this study. 
While extensive testing has been performed on these chemicals as single exposures at high 
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doses, there is a lack of testing using human relevant exposures (low dose and as a mixture) 
through multiple exposure routes. Further enhancements in inhalation methods testing are 
needed to explore and determine the best way to effectively and humanely perform inhalation 
studies on pregnant animals and their resulting offspring. The focus of my studies was on 
human relevant exposures during critical windows of susceptibility, to best mimic the VOC-
exposed families and young Marines living at Camp Lejeune. By only being able to examine 
the effects of drinking water exposure, these studies are missing the crucial component of 
inhalation exposure. 
  Findings from this project emphasize the need for further understanding of rat stain 
differences, particularly for mammary gland development, and the inclusion of mammary 
glands and early life exposures into standardized guidelines for toxicity testing. In both male 
and female rats, there were changes in mammary gland development with VOC exposure, 
which are not reported to be EDCs themselves, and in the male rats, adenocarcinoma 
formation only occurred in the high dose VOC-exposed group (although significance was not 
reached). The percentage of males forming adenocarcinomas in this 30 week study (9%) is 
much higher than previous spontaneous tumor studies in HSD rats or the rate found in 
controls in this study (0%). Further testing of human relevant exposures of VOCs, during 
critical windows of susceptibility are needed to assess hazards and risk for the development 
of male and female breast cancer. These low dose mixture effects in male and female rat 
mammary glands, as well as novel blood benzene levels following mixture administration in 
offspring, should be driving forces for further low dose evaluations of these VOCs.  
 
  
 
 
160 
 
REFERENCES 
1. Ward, I. L., O. B. Ward, J. D. Affuso, W. D. Long, 3rd, J. A. French, and S. E. 
Hendricks. 2003. Fetal testosterone surge: specific modulations induced in male rats 
by maternal stress and/or alcohol consumption. Horm Behav 43:531-539. 
 
2. Howard, B. A., and B. A. Gusterson. 2000. Human breast development. J Mammary 
Gland Biol Neoplasia 5:119-137. 
 
3. (IBCERCC), 2013. Breast Cancer and the Environment: Prioritizing Prevention. 
IBCERCC. 
 
4. Fenton, S. E. 2006. Endocrine-disrupting compounds and mammary gland 
development: early exposure and later life consequences. Endocrinology 147:S18-24. 
 
5. Brown, N.M. and C.A. Lamartiniere, Xenoestrogens alter mammary gland 
differentiation and cell proliferation in the rat. Environ Health Perspect, 1995. 103(7-
8): p. 708-13. 
 
6. Brown, N. M., P. A. Manzolillo, J. X. Zhang, J. Wang and C. A. Lamartiniere, 
Prenatal TCDD and predisposition to mammary cancer in the rat. Carcinogenesis, 
1998. 19(9): p. 1623-9. 
 
7. Fenton, S. E., J. T. Hamm, L. S. Birnbaum and G. L. Youngblood, Persistent 
abnormalities in the rat mammary gland following gestational and lactational 
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Sci, 2002. 67(1): p. 
63-74. 
 
8. nano, H., K. Suzuki, M. Onoda and K. Wakabayashi, Relationship between induction 
of mammary tumors and change of testicular functions in male rats following gamma-
ray irradiation and/or diethylstilbestrol. Carcinogenesis, 1996. 17(2): p. 355-60. 
 
9. Rothschild, T. C., E. S. Boylan, R. E. Calhoon and B. K. Vonderhaar, Transplacental 
effects of diethylstilbestrol on mammary development and tumorigenesis in female 
ACI rats. Cancer Res, 1987. 47(16): p. 4508-16. 
 
10. Rayner, J.L., R.R. Enoch, and S.E. Fenton, Adverse effects of prenatal exposure to 
atrazine during a critical period of mammary gland growth. Toxicol Sci, 2005. 87(1): 
p. 255-66. 
 
11. Stanko, J.P., M.R. Easterling, and S.E. Fenton, Application of Sholl analysis to 
quantify changes in growth and development in rat mammary gland whole mounts. 
Reprod Toxicol, 2014. 
 
12. Odum, J., I. T. Pyrah, A. R. Soames, J. R. Foster, J. P. Van Miller, R. L. Joiner and J. 
Ashby, Effects of p-nonylphenol (NP) and diethylstilboestrol (DES) on the Alderley 
 
 
161 
 
Park (Alpk) rat: comparison of mammary gland and uterus sensitivity following oral 
gavage or implanted mini-pumps. J Appl Toxicol, 1999. 19(5): p. 367-78. 
 
13. Sabourin, P. J., W. E. Bechtold, W. C. Griffith, L. S. Birnbaum, G. Lucier, and R. F. 
Henderson, Effect of exposure concentration, exposure rate, and route of 
administration on metabolism of benzene by F344 rats and B6C3F1 mice. Toxicol 
Appl Pharmacol, 1989. 99:421-444. 
 
14. Rudel, R. A., S. E. Fenton, J. M. Ackerman, S. Y. Euling, and S. L. Makris. 
Environmental exposures and mammary gland development: state of the science, 
public health implications, and research recommendations. Environ Health Perspect, 
2011. 119:1053-1061. 
 
15. ATSDR, Toxicological Profile for Benzene, U.S. Department of Health and Human 
Services, Editor. 2007, Agency for Toxic Substances and Disease Registry. 
 
16. ATSDR, Draft Toxicological Profile for Tetrachloroethylene, U.S. Department of 
Health and Human Services, Editor. 2014, Agency for Toxic Substances and Disease 
Registry. 
 
17. ATSDR, Draft Toxicological Profile for Trichloroethylene, U.S. Department of 
Health and Human Services, Editor. 2014, Agency for Toxic Substances and Disease 
Registry. 
 
18. ATSDR, Draft Toxicological Profile for Vinyl chloride, U.S. Department of Health 
and Human Services, Editor. 2006. 
 
19. Summerlee, A.J., D.J. Hornsby, and D.G. Ramsey, The dipsogenic effects of rat 
relaxin: The effect of photoperiod and the potential role of relaxin on drinking in 
pregnancy. Endocrinology, 1998. 139(5): p. 2322-8. 
 
20. Huff, J. E., J. K. Haseman, D. M. DeMarini, S. Eustis, R. R. Maronpot, A. C. Peters, 
R. L. Persing, C. E. Chrisp and A. C. Jacobs, Multiple-site carcinogenicity of benzene 
in Fischer 344 rats and B6C3F1 mice. Environ Health Perspect, 1989. 82: p. 125-63. 
 
21. Makris, S.L., Current assessment of the effects of environmental chemicals on the 
mammary gland in guideline rodent studies by the U.S. Environmental Protection 
Agency (U.S. EPA), Organisation for Economic Co-operation and Development 
(OECD), and National Toxicology Program (NTP). Environ Health Perspect, 2011. 
119(8): p. 1047-52. 
 
22. McCormick, D. L., R. G. Mehta, C. A. Thompson, N. Dinger, J. A. Caldwell, and R. 
C. Moon. 1982. Enhanced inhibition of mammary carcinogenesis by combined 
treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res 42:508-
512. 
 
 
 
162 
 
23. Russo, J., and I. H. Russo. 1996. Experimentally induced mammary tumors in rats. 
Breast Cancer Res Treat 39:7-20. 
 
24. Russo, I.H. and J. Russo, Developmental stage of the rat mammary gland as 
determinant of its susceptibility to 7,12-dimethylbenz[a]anthracene. J Natl Cancer 
Inst, 1978. 61(6): p. 1439-49. 
 
25. Carey, L. A., C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, G. 
Karaca, M. A. Troester, C. K. Tse, S. Edmiston, S. L. Deming, J. Geradts, M. C. 
Cheang, T. O. Nielsen, P. G. Moorman, H. S. Earp and R. C. Millikan, Race, breast 
cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006. 
295(21): p. 2492-502. 
 
26. Russo, J., Significance of Rat Mammary Tumors for Human Risk Assessment. Toxicol 
Pathol, 2015. 43(2): p. 145-170. 
 
27. Chavez-Macgregor, M., C. A. Clarke, D. Lichtensztajn, G. N. Hortobagyi and S. H. 
Giordano, Male breast cancer according to tumor subtype and race: a population-
based study. Cancer, 2013. 119(9): p. 1611-7. 
 
28.  Foulkes, W. D., I. M. Stefansson, P. O. Chappuis, L. R. Begin, J. R. Goffin, N. Wong, 
M. Trudel, and L. A. Akslen. Germline BRCA1 mutations and a basal epithelial 
phenotype in breast cancer. J Natl Cancer Inst, 2003. 95:1482-1485. 
 
29. ATSDR, Toxicological Profile for 1,2-Dichloroethene, U.S. Department of Health 
and Human Services, Editor. 1996, Agency for Toxic Substances and Disease 
Registry. 
 
30.  Vandenberg, L. N., C. M. Schaeberle, B. S. Rubin, C. Sonnenschein, and A. M. Soto. 
The male mammary gland: a target for the xenoestrogen bisphenol A. Reprod 
Toxicol, 2013. 37:15-23. 
 
31. King-Herbert, A., and K. Thayer. 2006. NTP workshop: animal models for the NTP 
rodent cancer bioassay: stocks and strains--should we switch? Toxicol Pathol 
34:802-805. 
 
32. NTP. 2011. Specifications for the conduct of studies to evaluate the reproductive and 
developmental toxicity of chemical, biological and physical agents in laboratory 
animals for the National Toxicology Program (NTP). National Toxicology Program, 
RTP, NC. 
 
 
 
